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                                         University of Pittsburgh, 2014 
 
Colorectal cancer (CRC) is currently the third most common form of cancer among 
developed nations. Given that nearly 50% of patients who undergo surgery and subsequent 
chemotherapy die of metastatic disease, novel therapeutic targets and more effective therapies are 
direly needed. Although genomic instability is known to promote colon carcinogenesis, many of 
the target genes that are mutated and drive tumorigenesis are yet to be elucidated. Based on a 
series of experiments and properties of hepatocyte growth factor (HGF), we hypothesized that 
HGF gene is a target of mutagenesis in human CRC. Therefore we aimed to test this hypothesis 
and determine the underpinning molecular mechanisms involved. 
We show that genomic instability provoked by DNA mismatch repair (MMR) deficiency 
causes deletion mutagenesis of an important repressor element in the HGF gene proximal 
promoter in human CRC cells. This promoter element, which we have named DATE 
(DeoxyAdenosine Tract Element) consists of a polyA tract of 30 deoxyadenosine bases. We show 
that shortening of DATE leads to the activation of the HGF promoter (which otherwise is silent 
in normal colon epithelium) hence creating an HGF-Met autocrine loop in CRC cells. We show 
that acquisition of HGF-Met autocrine signaling endows cancer cells with growth advantages, 
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which promotes cell survival and confers resistance to both modes of programmed cell death 
(apoptosis and necroptosis). 
 We show that growth factor signaling like the HGF-Met axis can directly impact RIPK-
1, a key mediator of necroptosis. This is achieved via tyrosine phosphorylation of RIPK-1 by 
activated Met, resulting in inhibition of RIPK-1 kinase activity. Furthermore, we discovered that 
Met activation causes RIPK-1 recruitment to the plasma membrane, its polyubiquitination (Lys-
48 linked chain) and its subsequent proteasomal degradation. We also found that aberrant HGF 
expression in tumor tissues is significantly correlated with low RIPK-1 and with poor clinical 
prognosis. Collectively, our results shed important mechanistic insights into the molecular 
mechanisms of human colon carcinogenesis and warrant further investigation of HGF-Met as a 
viable therapeutic target in CRC, especially in those subsets harboring HGF gene mutation. 
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1.0  INTRODUCTION 
1.1 COLORECTAL CANCER (CRC) 
1.1.1 CRC Epidemiology  
Colorectal carcinoma (CRC) is the third most common cause of cancer related death and 
the fourth leading cause of morbidity worldwide. CRC accounts for a staggering 9% of all human 
cancers, has an age standardized death rate of 18.8 per every 100,000 individuals, and affects both 
men and women equally 1.  During 2002, the most recent year for which international cancer 
statistics are available, an estimated 1 million new cases of CRC were diagnosed, and 529,000 
global deaths were reported 2.  Recent records indicate that cancers of the colorectum, along with 
those of the lung, breast, and prostate, will account for approximately 50% of all new cancer 
diagnosis 3. Distribution of CRC varies geographically, with 63% of all reported cases occurring 
in Australia, New Zealand, Canada, United States and Western Europe 4. Developing nations such 
as China, India, and parts of Africa and South America exhibit the lowest rates of incidence 5.  
Several risk factors, including age, personal medical history, and genetics, are associated with 
developing CRC. It is estimated that more than 90% of CRC diagnoses occur in individuals over 
the age of 50 and that the frequency is 50 times greater among those aged 60-79 in comparison 
to individuals under the age of 40 6,7. Incidence of CRC has however increased among younger 
persons over the last few decades and is now among the ten most commonly diagnosed cancers 
within the 20-49 age group 8. 
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As nearly 95% of sporadic CRCs develop from adenomas, an individual medical history 
of adenomas is considered to be a significant risk factor in developing CRC. Due to the long latent 
period of 5-10 years that is involved in the malignant transformation of benign adenomas, studies 
show the removal of adenomatous polyps and localized carcinomas can considerably reduce the 
risk of developing CRC at a future date 9.  The progression of benign adenomas to CRC is outlined 
in Figure 1A and the genes commonly altered at each stage of progression are shown in Figure 
1B. A personal history of bowel disease (in the form of ulcerative colitis or Crohn’s disease) that 
leads to inflammation of the colorectal mucosa or the bowel wall, is noted to increase the risk of 
developing CRC by 4-20 fold 4. A family history of CRC is observed in approximately 20% of 
the new diagnoses 6. The risk tends to be elevated in individuals with first degree relatives who 
developed adenomatous polyps prior to the age of 60, or those with first or second degree relatives 
who were diagnosed with CRC at any age 10. Approximately 5-10% of CRC results from 
hereditary conditions such as familial adenomatous polyposis (FAP) and hereditary nonpolyposis 
CRC (HNPCC) 1. HNPCC, which accounts for 6% of CRC, is characterized by tumor 
development of at an early age (<46 years of age) and is also associated with cancers of the 
endometrium, stomach, pancreas-biliary tract, small intestine, urothelium and ovary 11,12. FAP is 
caused by mutations in the APC tumor suppressor gene and is characterized by the early 
development of hundreds of polyps that may become malignant over time 11.  
Despite the strong associations observed between CRC and the above described genetic 
and age related risk factors, environmental factors are believed to be the largest contributor in 
CRC tumorigenesis. For instance, a diet high in animal fat and meat, while low in fruits and 
vegetables, lack of physical activity and a tendency towards obesity, cigarette smoking, alcohol 
consumption, as well as long-term residence in urban regions, are strong predictors of CRC 
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development 13. The linkage between diet and CRC largely stems from the role of animal fat and 
meat in exposing of the gut to large amounts of carcinogenic N-nitroso compounds, heme iron, 
and the potentially carcinogenic heterocyclic amines and polycyclic aromatic hydrocarbons 
produced during the high meat cooking temperatures. In contrast, high overall levels of physical 
activity and healthy body weight are associated with reduced risk of CRC. Preliminary studies 
regarding the underlying mechanisms have revealed that sustained physical activity raises 
metabolic rate, increases efficiency of oxygen uptake and gut motility, while reducing blood 
pressure and insulin resistance, contributing to lower overall tumorigenesis 1,14. Further 
supporting this theory, individuals with high-levels of abdominal fat, lower gut motility and lower 
metabolic efficiency showed higher incidences of CRC 6. Studies investigating the role of 
cigarette smoke in the onset of CRC showed that carcinogens in tobacco increase cancer growth 
within the colon and the rectum and that roughly 12% of CRC deaths are attributed to smoking. 
Heavy alcohol consumption is also believed to play a role in CRC tumorigenesis, as alcohol 
promotes the production of carcinogenic prostaglandins and free radicals and also acts as a solvent 
that increases the penetration of toxic compounds into the mucosal cells 1,15.  
CRC survival rates can vary between 90%-10%, depending on the disease stage at the 
time of diagnosis (Figure 1C). The tumor may be localized to carcinoma in-situ (stage 0), or have 
invaded the submucosa (stage I), invaded the muscularis propria into pericolorectal tissues (stage 
II), invaded regional lymph nodes (stage III), or metastasized to distant organs and structures 
(stage IV) 16. Due to increased access to healthcare, the overall 5-year survival for CRC has 
improved significantly over the last decade. The current five-year survival rate following CRC 
diagnosis is 60%, with only 6% of metastatic patients surviving this period 1,6. Nearly 50% of all 
CRC patients who undergo surgery and subsequent chemotherapy die of metastatic disease 17,18. 
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Due to the bleak prognosis of colon cancer, novel therapeutic targets and more effective therapies 
are direly needed. 
 
Figure 1. Progression from colorectal polyps to colorectal cancer   
(A) Schematic indicating the development of colon polyps into cancer. (B) Vogelgram indicating 
the associated molecular alterations during the progression of CRC. While only 10% of all 
adenomas become malignant, more than 95% of CRC develop from adenomas. (C) Histological 
images depicting the progression of CRC from Stage I through Stage IV. Adapted from Johns 
Hopkins Medicine Colorectal Cancer Center.  
1.1.2 Molecular pathways involved in CRC  
Accumulation of genomic alterations facilitated by the loss of genomic stability has long 
been known contribute to tumorigenesis and the clinical progression of sporadic and familial 
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forms of CRC 19. While chromosomal instability (CIN) is the form of genomic instability most 
commonly observed in CRC (85% of CRC), microsatellite instability (MSI) is also observed in a 
significant subset (15%–20%) of cancers 20. Both forms of genomic instability result in the 
alteration of key regulatory genes, promoting dysregulated cell proliferation, survival, 
angiogenesis, and escape from cell death. The most commonly altered signaling pathways in 
human CRC are Wnt/β-catenin (APC gene), epidermal growth factor receptor, 
RAS/RAF/mitogen-activated protein kinase (MAPK), phosphoinositide-3-kinase/Akt 
(PI3K/Akt), and transforming growth factor β  (TGFβ), and p53 19-21. 
Wnt/β-catenin pathway is primarily involved in developmental regulation and the 
postembryonic maintenance of intestinal stem cell populations. The protein product of the 
adenomatous polyposis coli (APC) gene participates in a destruction complex, which prevents 
activation of β-catenin in the absence of Wnt Signaling. Mutations in APC are observed in nearly 
all CRC patients harboring the hereditary familial adenomatous polyposis syndrome (FAP) as 
well as in 70-80% of the sporadic CRC cases. APC mutations are believed to be an early event 
during carcinogenesis. 95% of the known mutations in APC are nonsense or frameshift mutations 
that result in the formation of a truncated, nonfunctional version of the protein, which cannot 
participate in the β-catenin destruction complex. This leads to accumulation of β-catenin in the 
cytoplasm, allowing it to act as an unregulated transcriptional co-activator of genes important for 
cell survival and proliferation, ultimately contributing to colon carcinogenesis 21,22.  
EGFR is a receptor tyrosine kinase that is activated by dimerization and 
autophosphorylation upon the extracellular binding of its ligand. EGFR signaling is important in 
cell growth, proliferation and differentiation. EGFR protein expression is significantly elevated 
in 80% of CRCs. While the cause is still unclear, it is speculated that the elevated EGFR gene 
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copy number due to gene amplification and polysomy at chromosome 7 is responsible for the 
EGFR overexpression in at least a subset of CRC patients exhibiting the phenotype. Although 
rare, mutations leading to the ligand independent activation of the EGFR receptor were also 
observed in some patients. The abnormal activation of the EGFR signaling pathway through these 
mechanisms is believed to play a causative role in colorectal carcinogenesis and metastasis. 
Activation of the EGFR receptor in cells initiates the onset of several oncogenic signaling 
pathways including RAS/MAPK, PI3-AKT, phospholipase C, STATs and SRC/FAK. These 
signaling networks generally involve protein phosphorylation, recruitment of adapters, and the 
activation of transcription factors, eventually leading to increased cell survival and proliferation. 
When the EGFR signaling network is dysregulated, it may alter cell metabolism, disrupt normal 
cell cycle progression and prevent apoptosis, triggering the malignant transformation of the 
affected cells 21,23. Interestingly, several groups including ours have recently shown that other 
transmembrane growth factor receptors may also contribute to colorectal carcinogenesis. For 
instance, significant Met overexpression was found to provide a selective growth advantage to 
neoplastic colorectal cells at all stages of tumor growth and increase their metastatic potential 24-
26.  
The RAS family encodes small G-proteins, which are activated by the conversion of 
guanine diphosphate (GDP) to guanine triphosphate (GTP) and facilitates the downstream 
transduction of signals from extracellular receptors such as EGFR. KRAS, a prominent RAS 
family member, is mutated in 40% of sporadic CRCs. Point mutations in the codons 12 and 13 of 
KRAS are the most commonly observed lesions. These mutations cause the exchange of amino 
acids at the catalytic site, causing the protein to exist in the active GTP bound state and allowing 
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the recruitment of the serine/threonine kinase RAF, which phosphorylates and activates MAPK, 
promoting cell survival and proliferation 21,23,27.  
The PI3-AKT signaling pathway is directly activated by the phosphorylation of receptor 
tyrosine kinases such as EGFR and Met, and is important for stimulating cell proliferation and 
promoting escape from apoptosis. Gain of function mutations in exons 1, 2, 9, and 20 within the 
PIK3CA gene are observed in 15-30% of CRCs. These mutations are more commonly noted to 
occur in female CRC patients 21,28. Inactivating mutations in the tumor suppressor, PTEN, which 
encodes a phosphatase that antagonizes PI3-Akt signaling, are also observed in approximately 
9% of CRCs 28. 
TGF-β cytokines are involved in cell proliferation, differentiation, death, and extracellular 
matrix formation. The binding of TGF-β ligands to the transmembrane serine-threonine kinase 
receptor, TGF-β1, allows its interaction with TGF-βII (type II receptor) and activates the signaling 
pathway. TGF-β signaling causes the translocation of Smad 2/3/4 transcription factor complex to 
the nucleus, resulting in the transcription of cell cycle arrest genes such as the cyclin-dependent 
kinase inhibitor, P21.  Frameshift mutations in the TGF-βII gene are observed in 30% of 
colorectal carcinomas, with a majority occurring in microsatellite unstable cases. These TGF-βII 
mutations promotes escape from growth suppression signaling, contributing to colon 
tumorigenesis and metastatic invasion 29-31.  
The tumor suppressor, P53, which plays a role in facilitating cell cycle arrest, apoptotic 
cell death, cell differentiation, senescence, and angiogenesis, is also mutated in a wide variety of 
malignancies. Mutations in the P53 gene are observed in over 50-70% of CRCs and are associated 
with more aggressive disease forms 32.  
 22 
It is evident that multiple signaling pathways important for the regulation of cell 
proliferation, survival, death, angiogenesis and growth arrest are involved in the onset and 
progression of human CRC 21. A schematic illustration outlining the process of colon 
tumorigenesis is shown in Figure 1. Targeted therapies directed at the above-discussed pathways 
are currently being heavily investigated and are entering the forefront of CRC treatment protocols. 
1.1.3 Contemporary Treatment Strategies 
The introduction of novel surgical techniques and the standard use of 5-Fluorouracil (5-
FU) plus radiotherapy revolutionized CRC treatment during the 1980s and significantly reduced 
local recurrence rates. Currently, treatment strategies include preoperative chemotherapy, 
surgery, and postoperative adjuvant chemotherapy. Multiple new pre and postoperative chemo 
and radiotherapy combinations are currently being investigated for toxicity and efficacy in clinical 
trials in attempts to improve patient survival and quality of life, and reduce recurrence 33.   
Surgical success largely depends on the accuracy of the preoperative tumor staging 
process. Tumor staging is used to assess the depth of tumor infiltration into the tissue and to 
determine whether the tumor has spread to nearby lymph nodes or to distant metastatic sites. 
Currently, endorectal ultrasound imaging and pelvic MRI scans are primarily used to determine 
tumor staging. After determining the depth of tumor infiltration, surgery may be performed 34. 
While blunt digital resection has been the norm in colorectal tumor resection for many years, the 
use of novel, more precise surgical techniques, such as total mesorectal excision (TME) have 
dramatically reduced the local recurrence rate over the last two decades. Minimally invasive 
techniques such as lacroscopy and robotic surgery have also been utilized successfully to remove 
colorectal tumors and have resulted in low recurrence rates.  These techniques have become 
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popular in the tumor surgical resection arena due to the fact that they are performed as outpatient 
procedures and minimize patient trauma by resulting in sharp dissections that preserve the 
sphincter, minimize blood loss, and allow for rapid recovery 33.  
The use of pre and post-operative chemo-radiotherapy is utilized in order to reduce tumor 
volume when surgery alone is not a viable treatment option for the patient. 5-FU is the first-line 
of chemotherapy used in both pre and post-operative settings.  In controlled studies, it was noted 
that in comparison to patients who received only radiotherapy, those who received 5-FU in 
combination with radiotherapy fared well and had significantly lower rates of local recurrence, 
local metastasis, distant metastasis, and cancer related deaths 33. The chemotherapeutic agents, 
Oxiplatin and Irinotecan are often used in combination with 5-Fluouracil therapy and have shown 
improvements over single therapies in some patients. Phase III clinical trials, however, recently 
indicated that Oxiplatin does not significantly improve outcome of patients with locally advanced 
rectal cancer and thus should no longer be considered as a part of adjuvant chemotherapy 33. 
Additionally, an orally administered Fluoropyrimidine known as Capecitabine, has shown 
significant promise in clinical trials 35. Despite the clinical success of 5-FU in a majority of CRC 
patients, it is important to note that individuals exhibiting defective DNA mismatch repair and 
high microsatellite instability show little to no benefit from adjuvant 5-FU chemotherapy. (For 
detailed information on microsatellite instability please see the genomic instability subsection 
below). Following 5-FU administration, cells mistakenly incorporate the 5-FU metabolites into 
DNA and RNA. These lesions are generally recognized by the mismatch repair system as un-
repairable base mismatches and apoptosis is initiated. The observed CRC resistance to 5-FU in 
microsatellite unstable cells is largely believed to result from the inability to recognize the 5-FU 
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metabolites that are incorporated into the DNA during replication as base pair mismatches, and 
initiate cell death 36,37.   
 Targeted therapies have also been investigated for the treatment of CRC with a particular 
focus on monoclonal antibodies against EGFR (such as Cetuximab or Panitumumab), and the 
VEGF receptor (bevacizumab). Cetuximab is approved for the treatment of EGFR expressing, 
KRAS wild-type CRC. Although Cetuximab remains the only targeted therapy approved for 
clinical use in human CRC, the low toxicity and promising anti-tumor activity observed in early 
clinical trials have encouraged further development of other targeted therapies for CRC treatment 
33.  
1.1.4 Predictive CRC biomarkers used to assess patient prognosis 
A number of protein and genomic markers have been identified over the past two decades 
that have helped predict therapeutic response, chance of recurrence, metastasis and overall 
survival.  
Microsatellite instability (MSI) is characterized by the expansion or the deletion of 
oligonucleotide repeat regions. It is observed in a large subset of hereditary and sporadic cancers 
and is caused by defects in the DNA mismatch repair pathway (MMR). Incidence of microsatellite 
instability has shown promise in predicting patient response to therapeutic agents, and in assessing 
patient prognosis at various stages of the disease. For instance, it is noted that MSI instability high 
phenotype is primarily observed among stage II CRC patients (22%) and occurs at a much lower 
frequency in stage III (12%) and stage IV (3.5%) patients 38,39.  Although controversial, several 
studies have reported that MSI-H subpopulation of CRC patients display more favorable, stage-
adjusted prognosis in comparison to the MSS or the MSI-L patient subsets. For instance, initially 
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it was reported that a higher rate of disease-free survival was observed among 5-FU treated MSI-
H cancers (only within the stage III group), and that MSI-H patients of all stages who received 
only surgery fare better than the corresponding MSS or MSI-L counterparts 40,41. However, in 
contrast to these observations of favorable prognosis, a more recent large-scale study indicated 
that MSI-H patients who received 5-FU adjuvant chemotherapy showed significantly higher 
frequencies of intra-abdominal recurrence and local recurrence37. After multiple small and large-
scale studies, MSI status is now considered to be a robust prognostic marker in certain aspects of 
the clinical decision making process. It is most important in identifying and determining treatment 
strategies for the MSI-H CRC patient group who do not appear to benefit from 5- FU adjuvant 
chemotherapy 42. 
Another mutational signature that has shown predictive potential in CRC is widespread 
promoter methylation, a phenotype that is otherwise known as CIMP-high. The silencing of tumor 
suppressor promoters by the cytosine methylation of CpG islands is believed to be an early event 
in the process of carcinogenesis that is observed in 15-20% of sporadic cancers. Although 
conflicting, this phenotype was correlated with BRAF mutations, wild-type P53, right side tumors, 
older age, female sex, and poor differentiation 43,44. Further studies are however needed to confirm 
the clinical value of assessing for CIMP in patients. 
KRAS is currently the only CRC biomarker integrated into clinical practice. The rapid and 
nearly universal acceptance of KRAS as a valuable biomarker lies in the fact that KRAS mutations 
are highly prevalent in CRC and are strongly predictive of negative responses to anti- EGFR 
therapies (such as the anti-EGFR monoclonal antibody, Cetuximab). Screening for KRAS 
mutations are now routinely used to determine whether patients should receive anti-EGFR 
antibody therapy 42. It was recently shown that KRAS mutant cells are dependent on C-RAF 
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signaling, and are thus hypersensitive to the kinase inhibitor, Sorafenib. Phase I/II clinical trials 
involving the combination of Sorafenib with Irinotecan have shown promise in the treatment of 
KRAS mutant metastatic CRC 45.   
BRAF V600E mutations are mutually exclusive with KRAS mutations and occur in 8-15% 
of individuals with wild-type KRAS. It is strongly associated with low differentiation and poor 
patient prognosis. Clinical studies have shown that BRAF V600E mutant tumors are resistant to 
anti-EGFR therapies (such as Cetuximab and Panitumumab), and could be re-sensitized to 
Cetuximab when treated in combination with the kinase inhibitor, Sorafenib 42 . 
 Despite the large number of biomarkers recently identified in CRC, only KRAS 
mutations have been universally accepted and successfully incorporated into routine clinical 
practice. The lack of success observed with other biomarkers was largely a result of their 
inadequate predictive power and poorly defined study end points 42.  Our work, described below, 
identifies a novel HGF gene promoter mutation as a potential biomarker that is strongly predictive 
of negative patient prognosis in CRC.  
1.2 HGF-MET SIGNALING PATHWAY 
1.2.1 Overview of HGF-Met signaling  
Hepatocyte Growth Factor (HGF) is a stromal cell derived stimulator of epithelial cell 
growth and tissue regeneration. Dysregulated HGF expression contributes to tumor promotion 
and progression. It is secreted initially as a functionally inert precursor and later converted into 
its active form by extracellular proteases. The active form of HGF consists of a 60 kDa alpha 
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chain consisting of an amino-terminal hairpin loop and four kringle domains, as well as a 30 kDa 
beta chain, harboring a serine protease homology domain that lacks protease activity. The alpha 
and the beta chains are held together by one disulphide bond. The structure of HGF is detailed in 
Figure 2A. The functionally inert form of HGF is distributed largely in the extracellular matrix 
where it is sequestered by heparin-like proteoglycans. HGF elicits its extensive biological effects 
by binding to and activating its cell surface receptor, Met, a tyrosine kinase that is highly 
expressed on epithelial cells. The high-affinity site located on the HGF alpha chain can bind to 
the extracellular region of Met even prior to HGF processing and activation. The low–affinity site 
(located on the HGF beta chain) is exposed only following processing, and its binding to Met 
promotes activation of Met signaling 46,47.  
The Met receptor belongs to a unique subclass of receptor tyrosine kinases (RTKs) and is 
a widely expressed type I transmembrane tyrosine kinase cell surface receptor. It is highly 
expressed on epithelial cells. Met was initially classified as an oncogene due to its ability 
transform fibroblast cell lines. Met, like HGF, is proteolytically cleaved from a single chain 
precursor to form alpha and beta chains that are held by disulphide bonds. In its mature form, Met 
is a single-pass heterodimer with an extracellular region that encompasses that entire alpha 
subunit (50 kDA) linked to the beta chain (145 kDA), which traverses the plasma membrane. The 
intracellular portion harbors a juxtamembrane region, a kinase domain, and protein docking sites. 
The juxtamembrane domain contains a serine residue that down regulates kinase activity upon 
phosphorylation by protein kinase C or calcium/calmodulin dependent kinases, It also contains a 
tyrosine residue (Y1003), which binds the E3-ubiquitin ligase Cbl upon phosphorylation, 
targeting the Met receptor for ubiquitination mediated proteolytic degradation or receptor 
endocytosis 48,49. The detailed structure of Met is depicted in Figure 2B.    
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Figure 2. Structures of HGF and Met  
(A) Hepatocyte growth factor is synthesized as a single chain precursor and later processed into 
an active α- and β-chain heterodimer. HGF consists of six domains: an amino-terminal hairpin 
loop (HL), four kringle domains (K1–K4), and a serine protease homology (SPH) domain that 
lacks proteolytic activity. (B) The Met receptor is a single-pass transmembrane heterodimer 
consisting of an extracellular α-subunit, which is linked by a disulphide bond to the 
transmembrane β-subunit, that harbors the catalytic region.  The extracellular region of MET has 
several function domains, The sema domain encompasses the whole α-subunit and part of the β-
subunit, the PSI domain contains four conserved disulphide bonds. There are four IPT domains 
that connects the PSI domain to the transmembrane helix. The intracellular region contains a 
juxtamembrane sequence, a catalytic region, and multifunctional docking sites. Adapted from 49. 
    
Binding of the HGF heterodimer results in Met receptor dimerization and trans-
phosphorylation of the kinase residues in the catalytic domain, followed by phosphorylation of 
the docking tyrosine residues in the carboxy-terminal. The C-terminal tail of Met is necessary and 
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sufficient for signal transduction. Met interacts with various scaffolding adapters such as Shc and 
Gab-1, and signaling proteins, to promote efficient downstream signaling activation. These 
adaptor proteins provide extra binding sites for PI3K, SHC, SHP2 and other signaling proteins 
and mediators 49.  
Canonical signaling pathways activated by HGF-Met complex include mitogen-activated 
protein kinase 1 (ERK1) and ERK2, the phosphoinositide 3-kinase–Akt (PI3K–Akt) axis, signal 
transducer and activator of transcription proteins (STATs), Jun amino-terminal kinases (JNKs) 
and p38, and the nuclear factor-κB inhibitor-α (IκBα)–nuclear factor-κB (NF-κB) complex. In the 
activation of the ERK1/2, GRB2-SOS complex associates with the Met at the multifunctional C-
terminal docking site, leading to Ras activation, followed by Raf, and then MEK1/2. The 
phosphorylation of ERK1/2 by MEK1/2 results in their translocation to the nucleolus where 
several transcription factors involved in the G1-S phase cell cycle phase transition are 
phosphorylated and stabilized. Activation of the PI3-Akt axis, which may be activated directly 
by Met or indirectly by Ras, results in the tethering of plextrin homology domain (PH) containing 
molecules to the plasma membrane. The most prominent of these molecules is the Ser/Thr kinase 
Akt, which suppresses the apoptosis activation by E3 ubiquitin ligase MDM2, inactivates the 
proapoptotic BCL-2 antagonist of cell death (BAD), and promotes survival by inactivating 
glycogen synthase kinase 3β that normally reduces the expression of cell cycle regulators such as 
Myc and cyclin D1. Activation of JNKs and p38 by a similar pathway results in alteration of a 
diverse variety of cellular processes including cell proliferation, differentiation, and apoptosis. 
Met-mediated phosphorylation leads to homodimerization of STATs (namely STAT3). The 
dimers then translocate to the nucleus and act as transcription factors, regulating the expression 
of cell proliferation and differentiation gens. Finally, Met activation also leads to the activation 
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of the NF-κB pathway, indirectly by way of the PI3-AKT and Src signaling pathways. 
Phosphorylation mediated degradation of the inhibitory proteins, IκBs, results in the release of 
NF-κB, which translocates to the nucleus and promotes transcription of various proliferation-
associated and anti-apoptotic genes (Figure 3).  Met signaling may be intensified, particularly in 
tumors, by the receptor’s interaction with the α6β4 integrin. Integrin can act as a supplementary 
docking platform amplifying the Met receptors’ ability to transduce cellular signals. Met can be 
dephosphorylated at the catalytic activation sites and the docking sites by several protein tyrosine 
phosphatases (PTPs), including the density enhanced phosphatase 1(DEP1) and leukocyte 
common antigen related phosphatases 49,50.  
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Figure 3. Multiple signal pathways are activated by HGF-Met signaling  
Binding of HGF to the Met receptor activates multiple signaling pathways important for cell 
survival, proliferation and prevention of cell death. Adapted from 49. 
 
HGF promotes cell growth, survival, proliferation, differentiation, and tumorigenesis 
(Figure 4). HGF-Met signaling is observed to be crucial for the growth and survival of 
hepatocytes and placental trophoblast cells during early development. The importance of HGF-
Met signaling is evidenced by the fact that HGF or MET null embryos have significantly smaller 
livers, a hypomorphic placental phenotype, and compromised maternal and fetal gas exchange, 
that leads to in utero death of the organism by day 16 of embryonic development 49. The absence 
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of HGF-Met signaling also results in complete ablation of proliferation and motility of a group of 
muscle progenitors, and significantly impairs the growth of the nervous system 51. HGF-Met 
signaling also plays a crucial role in the regeneration of organs. In vitro studies of three 
dimensional collagen matrix culture conditions revealed that HGF promotes the partial epithelial-
mesenchymal transition of normal epithelial spheroids, leading to cell re-differentiation and 
tubulogenesis that is necessary for organ regeneration. In vivo studies have shown that HGF-Met 
signaling is indispensable for the regeneration of the liver and kidney following both acute and 
chronic organ damage. HGF production is greatly increased following liver damage, providing 
hepatocytes with rapid mitogenic potential through Met-mediated proliferative and anti-apoptotic 
stimuli.  In conditional mutant mice lacking MET in the liver, organ regeneration abilities are 
severely impaired following acute and chronic organ insults such as liver toxicity or partial 
hepatectomy 52. HGF-Met signaling also has a protective role in the kidney. It prevents renal 
failure during tubular necrosis by promoting the survival and proliferation of renal cells, thus 
facilitating kidney regeneration 49,53. HGF-Met signaling plays an important role during would 
healing. Mice harboring a conditional deletion of MET in the epidermis were unable to generate 
hyper-proliferative marginal keratinocytes necessary for repopulation of the wounded region. 
Furthermore, HGF is also believed to be important for cell locomotion to the de-epithelialized 
wounded region 49,54.  
 33 
 
Figure 4. Roles of the HGF-Met signaling pathway  
HGF-Met signaling is a crucial player in executing multiple cellular processes. HGF acts as a 
mitogen (promoting cell proliferation), motogen (promoting cell growth), and a morphogen 
(promoting cell differentiation), and stimulates cell survival. Dysregulated HGF-Met signaling is 
associated with malignant transformation and tumor progression. 
 
1.2.2 Regulation of HGF-Met signaling 
Given its crucial role in promoting cell survival and growth, the HGF/Met signaling axis 
is tightly regulated by a number of mechanisms at both the ligand and receptor levels. At the 
receptor level, internalization of the activated receptor and proteolytic cleavage are employed to 
attenuate Met signaling. Following ligand binding and activation, Met is monoubiquitinated by 
the E3 ubiquitin ligase, CBL, which targets the receptor for lysosomal degradation. Regulated 
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proteolysis of Met is also used as a mechanism to down-regulate Met levels to prevent excessive 
activation of the pathway 49,50.  
HGF abundance is regulated primarily through gene expression in a cell type-specific 
manner. Inducible HGF production is limited to cells of mesenchymal origin while the HGF 
promoter is transcriptionally silenced in epithelial cells. HGF produced by the stromal cell 
compartment is largely sequestered in the extracellular matrix, allowing it to only act in a 
paracrine fashion on epithelial cells 46,55.  In vitro studies have revealed that HGF gene expression 
in stromal cells is inducible by a variety of signaling molecules, including estrogen, 
desamethasone, TGF-β, TNFα, as well as other cytokines and tissue loss (Figure 5). During 
wound repair for instance, interleukin-1 and 6, tumor necrosis factor-α and transforming growth 
factor-β (TGF-β) were observed to cause transcriptional up-regulation of HGF in fibroblasts and 
macrophages, but not epithelial cells 56.     
Transcription factors like C/EBPβ, AP2, COUP-TF (chicken ovalbumin upstream 
promoter transcription factor), SP1 and SP3, and nuclear hormone receptors such as PPARγ and 
estrogen receptor were found to regulate HGF gene expression by binding to their associated sites 
in the HGF basal and proximal promoter 57-59. In vivo studies using transgenic mice (harboring 
chimeric HGF consisting of mouse HGF promoter of varying lengths fused to a reporter gene) 
have identified a number of regulatory elements located within 1 kb upstream of the basal 
promoter that are necessary for HGF promoter activation. Several studies have confirmed that 
these upstream regulatory regions dictate HGF expression by directly binding nuclear factors 
and/or modifying chromatin dynamics, significantly altering the interaction between transcription 
factors and their cognate binding elements. These mechanisms allow for the tight regulation of 
inducible HGF expression in mesenchymal cells, and mediate the effective silencing of the HGF 
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gene in epithelial cells 57-64. For instance, a DNA element located at 872−860 bp from the 
transcription start site contains an imperfect estrogen receptor element. Binding of COUP-TF, a 
nuclear orphan receptor belonging to the steroid/thyroid hormone receptor superfamily, to this 
DNA element silences HGF expression. On the other hand, the binding of the estrogen receptor 
to the site alleviates COUP-TF repression of transcription, causing activation of the HGF 
promoter. This was demonstrated using transgenic mice harboring either 2.7 kb or 0.7 kb 
promoter regions fused to a reporter. In contrast to mice harboring the entire 2.7 kb promoter 
region, mice with the shortened, 0.7 kb promoter lacking the estrogen receptor like regulatory 
element, did not show promoter activation in response to estradiol injection 58. Additional 
mapping studies have revealed that in the absence of certain upstream regulatory elements, HGF 
core promoter within 100 bp upstream of the transcription start site is “promiscuous”, indicating 
that it is active in both epithelial and mesenchymal cells (although to a lesser degree in epithelial 
cells). These works further validate the fundamental role played by upstream regulatory regions 
in controlling HGF promoter activity 57-59 (Figure 6).  
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Figure 5. HGF-Met signaling is regulated in a cell-type specific manner 
HGF gene expression is silenced in epithelial cells and HGF production is limited to stromal cells. 
Met is expressed in both epithelial and mesenchymal cells. HGF gene expression is induced in 
the stromal cell compartment by various signaling molecules including estrogen, desamethasone, 
TGF-β, TNFα, and a number of cytokines. HGF then activates Met signaling in epithelial cells in 
a paracrine manner.  
 
 
 
 
 
 
 
 
 
Figure 6. Regulation of cell-type specific HGF expression 
Inducible HGF expression in mesenchymal cells is at least in part controlled by regulatory regions 
located within 1kb upstream of the basal promoter. These regulatory elements dictate the binding 
of various transcription factors, such as C/EBPβ, AP2, SP1,SP3 and nuclear hormone receptors 
such as PPARγ, estrogen receptor and COUP-TF to their cognate binding sites.  
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 Recently, we identified novel regulatory cis-acting element located approximately 730 
bp from the basal promoter of the human HGF gene. This element represses HGF gene 
transcription in epithelial cells by modulating chromatin structure and by regulating the 
recruitment of transcription enhancers to the promoter region. We named this regulatory element, 
as DATE (DeoxyAdenosine Tract Element) as it consists of a poly-A-tract of 30 deoxyadenosines 
(Figure 7A). We found that wild-type, full-length DATE (30 deoxyadenosines), fosters tight 
chromatin condensation and promote the binding of transcriptional repressors to the HGF 
promoter.  When the fidelity of this region is compromised by reduction in the number of 
adenosines, the DATE region promotes release of repressors, chromatin remodeling and 
recruitment of transcriptional activators such as C/EBPβ and PARP1/2 to the HGF promoter, 
leading to HGF transcription. Notably, we reported that DATE is a subject of deletion 
mutagenesis in human breast ductal carcinoma tissues and its shortening leads to loss of its 
repressor function, leading to HGF promoter activation in these cells 65 (Figure 7B).  
Collectively, these works indicate that in normal cells, HGF-Met signaling is tightly 
regulated in the stroma and entirely suppressed in the epithelia. Additionally, dysregulation of 
these regulatory mechanisms is associated with cancer. Although the detailed molecular 
mechanisms governing cell type-specific expression of HGF remain obscure to some degree, 
based on the above described promoter studies and other works, we now understand that silencing 
of HGF expression in epithelial cells is at least in part controlled by multiple cis acting regulatory 
elements in the region 1 kb upstream from the start site of the HGF promoter 57-64. While these 
studies represent significant milestones in our understanding of HGF gene expression, the 
complete mechanisms responsible for HGF regulation remain to be elucidated. 
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Figure 7. Structure and function of DATE 
(A) DATE (deoxyadenosine tract element) is a regulatory cis-acting region located approximately 
730 bp from the basal promoter of human HGF gene. In its wild-type form, DATE consists of 30 
deoxyadenosines. (B) Wild-type DATE silences HGF expression by maintaining chromatin in a 
highly condensed form, promoting the binding of repressors to the promoter and by preventing 
the binding of transcriptional activators to their cognate promoter elements. DATE shortening 
causes repressor binding loss, chromatin remodeling, and the recruitment of transcriptional 
activators C/EBP-β1 and PARP1/2 to the promoter, leading to HGF promoter activation and gene 
expression. Adapted from 65. 
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1.2.3 HGF-Met signaling in cancer 
Transcriptional activation of Met in cancer is commonly induced by hypoxia, 
inflammatory cytokines, and the pro-angiogenic factors abundant in the tumor stroma. Activation 
of Met in these already transformed cells exacerbates the malignant phenotype by promoting 
increased cell proliferation, survival and migration. Cell lines that overexpress MET or HGF were 
noted to be tumorigenic and metastatic when introduced to nude mice, while down regulation of 
MET was noticed to decrease the tumorigenic potential of the cells 66. Concurring with the model 
that invasive cells simply resume the behaviors of early development, Met driven aggravation of 
cancer involves dysregulated stimulation of nearly all of the signaling pathways normally 
operative during embryonic development and organ regeneration.   
The oncogenic potential of the HGF-Met signaling axis is substantiated by the fact that a 
number of epithelial and mesenchymal human cancers exhibit HGF and Met mutations that lead 
to hyper or aberrant activation of the pathway. Although dysregulated Met activation is often a 
late event that intensifies tumor progression, genetic lesions in HGF or MET are observed to play 
a causative role in the onset and the maintenance certain malignancies. In these cases, persistent 
activation of the HGF-Met signaling pathway is required to maintain the hyper-proliferative 
phenotype, and thus the cancer cells are said to be oncogenically addicted to HGF-Met signaling. 
Somatic gene amplification leading to MET overexpression was observed in colorectal, gastro-
esophageal, gastric, ovarian and non-small-cell lung cancers and was associated with adverse 
prognostic outcomes. Sequencing of MET from individuals with hereditary kidney cancer 
syndromes revealed the existence of germline missense point mutations in the kinase domain 
causing ligand independent activation of Met. Mutations in the intracellular region of the Met 
receptor have also been noted in sporadic hepatocellular carcinoma, papillary renal cells 
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carcinoma, and gastric tumors and head and neck squamous cell carcinomas. A chromosomal 
translocation leading to the production of Tpr-Met fusion protein (which lacks the inhibitory 
juxtamembrane portion of Met and is thus constitutively active) was observed in human gastric 
carcinomas. Autocrine Met signaling (which occurs when epithelial cells express both the HGF 
ligand and the Met receptor) due to aberrant activation of HGF transcription or the overexpression 
of HGF activator protein, are observed in osteosarcomas, rhabdomyosarcomas, gliomas, cancers 
of the thyroid and lung 48,66. In congruence with these findings, we recently showed that a novel 
mutation of the HGF gene promoter region (designated as DATE) leads to the autocrine activation 
of HGF-Met signaling loop in a subset of breast cancers and contributes to breast carcinogenesis 
and tumor progression 65.  
1.2.4 Therapeutic Strategies targeting HGF-Met signaling 
The initial efforts to halt HGF-Met signaling in cancer primarily focused on preventing 
HGF ligand binding to Met using antagonist competitors such as NK4, a molecule which 
resembled the N-terminal hairpin region and the four kringle domains of HGF. NK4 showed 
robust antagonist and promising anti-tumor abilities in several mouse tumor models, however its 
large-scale therapeutic application was limited by its inability to induce significant tumor 
regression in cancers involving ligand-independent Met activation 67. Similar to NK4, 
neutralizing HGF antibodies were explored for their potential to inhibit ligand-dependent Met 
activation in tumors. Although encouraging results were observed in mouse models, given that a 
minimum of three antibodies (with varying pharmacodynamics qualities) against different HGF 
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epitopes were necessary to completely inhibit Met, concerns about the practicality of the approach 
have delayed its clinical application 48.  
Strategies directly targeting the Met receptor, which can be used in clinical situations 
involving both ligand dependent and independent activation of signaling, have shown promise in 
both mouse models and clinical trials. These approaches include inhibiting the tyrosine kinase 
activity of Met, blocking its interaction with downstream signaling effectors, decreasing cell 
surface expression and hindering receptor dimerization. Other potential therapeutic strategies 
include the introduction of polypeptides that compete with downstream effectors for access to the 
Met docking site, RNA interference to promote Met silencing, and the use of dominant-negative 
Met constructs that lead to nonfunctional Met dimerization.  The low efficiency and difficulty in 
delivery associated with these strategies have led to reservations regarding their clinical 
relevance. To date, small molecule ATP-competitive and allosteric inhibitors of Met activation 
have shown the most promise due to their high efficacy, however, the lack of specificity and 
potential for systemic side effects have raised concerns. There are a number of Met kinase 
inhibitors and anti-HGF therapies in phase I and II clinical trials for the treatment of lung, renal, 
gastric, brain and CRC 48,68.  For instance, AMG 102 is a monoclonal HGF neutralizing antibody 
currently in phase I clinical trials for the treatment of patients with unresectable locally advanced 
or metastatic gastric adenocarcinomas, being used in conjunction with the chemotherapeutics 
agents Epirubicin and Cisplatin.  AMG208 and AMG337 are two additional Met kinase inhibitors 
that are currently in clinical trials for the treatment of adults with a variety of advanced solid 
tumors 69.  
The targetable nature of HGF-Met signaling in colorectal carcinoma was recently 
demonstrated using a selective small molecule Met kinase inhibitor, ARQ 197 (Tivantinib). In 
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vitro assays using ARQ 197 showed a dose and a time-dependent decrease in the proliferative 
capacity of CRC cell lines, and ARQ 197 injection in mice bearing CRC cell line xenografts 
caused inhibition of tumor growth 70. In phase I clinical trials, Tivantinib was well tolerated and 
showed encouraging anti-tumor activity in patients with metastatic CRC in conjunction with the 
chemotherapeutics, Irinotecan and Cetuximab 71. While targeting Met is relatively new and 
presents numerous challenges with regard to efficacy, specificity and delivery, further 
development and improvement of targeting approaches has vast therapeutic potential in both 
cancer and non-neoplastic pathologies.  An overview of HGF-Met targeting strategies currently 
being investigated is depicted in Figure 8.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Strategies currently being investigated to inhibit HGF-Met signaling 
Adapted from 72. 
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1.3 GENOMIC INSTABILITY IN CANCER 
Originally outlined hallmarks of cancer include sustained proliferation, insensitivity to 
growth inhibitory and death signaling, replication immortality, sustained angiogenesis, ability to 
induce local and distant metastasis, abnormal metabolic pathways, immune system evasion, 
inflammation and genomic instability.  Although only recently added to the list of cancer cell 
hallmarks, genomic instability is noted to be prominent in nearly all cancers, and can occur in the 
form of chromosomal instability (CIN) or microsatellite instability (MSI) 19,73.  
1.3.1 Mechanisms of chromosomal instability 
Fidelity of chromosome segregation is tightly controlled in normal cells, but is often 
dysregulated in cancer. CIN is hypothesized to result from alterations in classical caretaker genes 
such as DNA repair and mitotic checkpoint genes, or due to oncogene-induced DNA replication 
stress 19. While the exact mechanisms of how caretaker gene mutations or oncogene- mediated 
replication stress eventually lead to the onset of CIN are not fully understood, it is generally 
believed that they induce multiple cellular defects, such as altered centrosome duplication, faulty 
spindle assembly, and telomere dysfunction. These defects cause inaccurate attachment of 
microtubules to chromosomes, resulting in the lagging of chromosomes in anaphase, mis-
segregation, and eventually the presentation of the CIN phenotype. For instance, centrosome 
duplication increases the number of potential erroneous spindle attachment points, therefore 
rapidly overwhelms the cells’ natural repair mechanisms, promoting chromosome mis-
segregation during cell division. When there is aberrant activation of the spindle assembly 
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checkpoint, mis-segregation of chromosomes occurs, leading the formation of cells with the 
incorrect number of chromosomes and high tumorigenic potential 74.  
1.3.2 Chromosomal instability in cancer 
In cancer, CIN manifests itself in the form of aneuploidy, sequence changes, base 
substitutions, deletions, insertions, chromosomal rearrangements, and gene amplification. Given 
that 70% of solid tumors display these characteristics, it is strongly argued that chromosomal 
instability is a driver of tumorigenesis and an important player in cancer progression 74. The CIN 
pathway is postulated to be a key player in the onset and progression of a majority of CRCs and 
is associated with poor patient prognosis. Large-scale sequencing analysis has revealed that 
cancers displaying CIN commonly show alterations in cell cycle caretaker genes including, the 
TP53 tumor suppressor, the DNA damage checkpoint gene, ATM, and the cell cycle regulator, 
CDKN2A. Dysregulation of these caretakers alters cell cycle dynamics, resulting in the mis-
segregation of chromosomes during replication and fostering instability throughout the genome. 
As mentioned above, CIN can also result from excessive DNA replication stress induced by 
activating mutations in classical oncogenes such as EGFR, the small GTPase, RAS, or the 
inactivation of the PTEN tumor suppressor gene, RAS mutations are frequently observed in 
pancreatic and lung carcinomas, while a large portion of glioblastomas present PTEN and EGFR 
mutations 74,75.  
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1.3.3 Mechanisms of microsatellite instability  
Microsatellite instability (MSI), which is characterized by the expansion or the deletion 
of oligonucleotide repeat regions, is observed in a large subset of hereditary and sporadic cancers. 
Microsatellite instability is caused by defects in the DNA mismatch repair pathway (MMR) that 
may be caused by aberrant CpG methylation of MLH1, or point mutations in MLH1, MSH2 or 
other MMR pathway genes. MMR system repairs the base-base mismatches and unmatched 
insertion-deletion DNA loops 76 (Figure 9A). When these lesions are left unrepaired, permanent 
mutations that may alter cell behavior and promote tumorigenesis are reported to occur. As such, 
the MMR system plays a key role in maintaining DNA replication fidelity and serves as a first 
line of defense against malignant transformation. Cells harboring MMR deficiency are unable to 
repair the nucleotide slippage errors that frequently occur during DNA replication and thus 
experience genomic alterations in the forms of frameshift or point mutations, as well the 
shortening and the lengthening of nucleotide repeat genomic regions. Repetitive nucleotide 
regions are particularly sensitive to mutagenesis in the absence of proficient MMR, as these 
regions commonly experience nucleotide slippage errors during replication (Figure 9B). While 
many repetitive genomic regions consist of noncoding DNA, when a mismatch or an erroneous 
deletion/insertion loop that occurs in a repetitive coding region of a key regulatory gene remains 
unrepaired, it may provide cells with an increased growth advantage and result in carcinogenesis 
19,76. This cause-effect relationship between MMR defects and tumorigenesis was demonstrated 
in experiments involving mice with knockout mutations in each of the MMR genes. Mice lacking 
functional MMR systems developed the expected mutator phenotype and exhibited a 
predisposition to develop various carcinomas, lymphomas and sarcomas 77.  
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Figure 9. DNA mismatch repair system maintains genomic fidelity during replication 
DNA mismatch repair (MMR) system (DNA repair system is utilized for recognizing and 
repairing (A) erroneous mis-incorporation of bases and (B) insertion/deletion loops and that can 
arise during DNA replication. The repair system consists of protein complexes involving MLH1, 
MSH2, among others. (C) Repetitive genomic regions such as DATE (see section 1.2.2) are 
particularly prone to the formation of insertion/deletion loops and thus replication errors. In MMR 
deficient cells, DATE deletion loop would be not repaired, leading to the formation of shortened, 
mutant DATE variant. Adapted from 78. 
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1.3.4 Microsatellite instability in cancer 
Lynch syndrome, often referred to as hereditary nonpolyposis CRC (HNPCC), is a 
hereditary disorder that occurs due to germline mutations in the mismatch repair genes MSH2, 
MLH1, and PMS2, and is inherited in an autosomal dominant manner. MSI phenotype is observed 
in up to 90% of lynch syndrome associated diseases, including colorectal, stomach, small 
intestine, liver, gallbladder duct, upper urinary tract, brain and skin cancers, and fosters the early 
development of benign or precancerous polyps. Additionally, women with lynch syndrome have 
a significantly increased risk of developing ovarian, uterine and endometrial cancers 79,80. Aside 
from its role in hereditary malignancies, MSI is also observed in a number of sporadic cancers, 
including colon, endometrial, gastric, and lung carcinomas, as well as several lymphomas. 
Approximately 15% of CRCs, 20-30% endometrial cancers, and 10% of gastric cancers, are 
characterized by MMR deficiency and exhibit high levels of MSI.  While germline mutations in 
mismatch repair genes were causative of the hereditary lynch syndrome cancers, epigenetic 
silencing of MLH1 via CpG methylation was found to be the most common lesion observed in 
sporadic cancers exhibiting the MSI phenotype 80,81.  
Significant strides have been made in identifying the genomic targets of defective MMR, 
and in discerning the clinico-pathological behaviors of tumors harboring MSI. In MSI high 
cancers, the expansion and deletion of sequence-repeats leads to the accumulation of base 
substitutions and frameshift mutations in genes responsible for cell survival, proliferation, and 
apoptosis, such as transforming growth factor receptor type II, insulin-like growth factor type II 
receptor, pro-apoptotic BAX genes, transcription factor E2F-4, and tumor suppressor genes such 
as APC and PTEN. Unlike tumors exhibiting CIN, microsatellite unstable tumors do not show 
gross genomic lesions or aneuploidy, and instead have diploid genomes, display proximal tumor 
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location, a mucinous phenotype, and are poorly differentiated with heavy lymphocyte infiltration 
76,82.  
1.3.5 The use of microsatellite instability as a diagnostic and a prognostic marker in 
cancer 
MSI has been used as a helpful cancer diagnostic tool in detecting lynch syndrome, as 
nearly all patients presenting lynch syndrome tumors show mismatch repair defects and instability 
at nucleotide repeat genomic regions. Furthermore, in sporadic human CRC, MSI is maintained 
to have prognostic significance at particular disease stages and is believed to predict the patient 
response to several commonly utilized chemotherapeutic agents 82. As described in above 
sections, MMR system detects DNA damage and promotes apoptosis in cells with irreparable 
levels of damage. Therefore, MMR deficiency predisposes cancer cells to be resistant to treatment 
with DNA damaging alkylating agents such as Temozolomide, or Procarbazin and Cisplatin, by 
failing to detect the formation of DNA adducts and consequently preventing the onset of 
apoptosis. Furthermore, MMR deficient CRC patients are predicted to receive little benefit from 
5-FU adjuvant chemotherapy that is commonly utilized in clinical settings. The resistance to 5-
FU is believed to result from the inability of MMR deficient cells to recognize the 5-FU 
metabolites that are incorporated into DNA as mismatches, and self-eliminate via apoptosis 82,83. 
Despite the fact that hundreds of microsatellite markers have been identified to date, it is 
yet unclear how many and which loci should be used to robustly evaluate MSI in clinical settings. 
In order standardize the screening of MSI internationally, a set of parameters known as Bethesda 
guidelines were established during the last decade. These guidelines specify that at least five loci 
must be assessed for instability.  If one of the five loci were unstable, then the tumor is classified 
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as MSI-low (MSI-L), and if two or more loci were altered, then the tumor is determined to be 
MSI-high (MSI-H).  Cancers exhibiting MSI can be further divided into two groups: those that 
show instability primarily at mono- and di-nucleotide markers, and those that exhibit instability 
at larger tri- or tetranucleotide repeats. It has been observed that endometrial colonic, and gastric 
tumors generally belong the first group, while bladder and lung cancers with MSI belong the latter 
group 84. As investigators were using many different microsatellite markers to assess instability 
and thus obtaining varying frequencies of MSI in the same cancer type, in an attempt to 
standardize the protocol, the National Cancer Institute (NCI) recently recommended a five-
marker reference panel. The panel consists of two mononucleotide loci, BAT-25 and BAT-26, and 
three dinucleotide loci D2S123, D5S346, and D17S250, and were chosen due to the fact that these 
loci were ubiquitously altered in nearly all MMR deficient cancers 84,85. The recommended 
reference panel is expected to change over time as more sensitive and clinically applicable 
markers are identified through novel research.  
 As we stride forward into the era of personalized medicine, it is important to recognize 
that MMR deficient tumors are a clinico-pathologically distinct subset that must be identified and 
treated accordingly. Given that MMR deficiency antagonizes many commonly utilized 
chemotherapeutic agents 83, it is pertinent that we continue to uncover novel, more reliable 
markers for MSI detection, and identify clinically relevant targets of defective MMR, in order to 
improve the therapeutic strategies available for this patient population.  
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1.4 MAJOR PATHWAYS OF CRC CELL DEATH 
1.4.1 Apoptosis 
Apoptosis is a form of programmed cell death that was first described by Kerr et al. in 
1972 86. The ability of certain cells to escape apoptotic cell death is now identified as a hallmark 
of cancer and is believed to play a major role in malignant transformation 87. Cells undergoing 
apoptotic cell death are characterized by cell shrinkage, nuclear condensation, aggregation of 
chromatin at the nuclear membrane, and fragmentation of the cell into membrane bound vesicles, 
known as apoptotic bodies. Apoptosis is implemented by the proteolytic enzymes known as 
cysteinyl aspartate-specific proteases (Caspases). Caspases are classified as either initiators 
(Caspases 8,10) or executioners (Caspases 3,6, and 7), and participate in the extrinsic and intrinsic 
death pathways. In the extrinsic, otherwise known as the death receptor pathway, tumor necrosis 
factor (TNF), TNF-related apoptosis-inducing ligand treatment (TRAIL), or Fas ligands bind to 
their cognate receptors, and in congruence with adapter molecules such as Fas-associated death 
domain (FADD) or TNF receptor–associated death domain, causes the cleavage and the activation 
of the initiator Caspases. These Caspases then cleave and activate the executioner Caspases, 
resulting in apoptotic cell death. In the intrinsic mitochondrial pathway, apoptotic signaling 
results in the release of cytochrome c into the cytosol. Cytochrome C then interacts with the 
apoptosis-activating factor-1 (Apaf-1), ATP, and pro-Caspase 9 to form a complex known as the 
apoptosome. This complex then cleaves and activates Caspase 9, which then cleaves and activates 
the executioner Caspases 3,6, and 7, causing the onset of apoptosis 88. 
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1.4.2 Autophagy 
Autophagy involves the self-mediated lysosomal degradation of cellular contents. During 
this process, a portion of the cytoplasm becomes enveloped in a double membrane vesicle known 
as the autophagosome, which then fuse with the lysosome to form the autolysosome. Within this 
membrane bound structure, the cellular contents undergo hydrolytic degradation. While 
autophagy occurs in normal cells during tissue remodeling and stress conditions, it is particularly 
associated with certain pathologies, including viral infection, neurodegenerative diseases and 
cancer 89.  
Autophagy may be utilized to promote both cell survival and death. In survival, autophagy 
may be used by cells to relieve the burden of excess protein and damaged organelles, as well as 
to conserve energy during nutrient depravation conditions by facilitating the recycling of amino 
acids for new protein production 90. It was shown that induction of extreme stress (nutrient 
depravation and hypoxia) in human CRC cells results in the onset of autophagy and cell death in 
response to chemotherapeutic agents. The molecular depletion of the autophagy executing 
proteins, beclin-1 or ATG5, enhanced the sensitivity of the colorectal tumor cells to oxiplatin 91. 
Furthermore, the term autophagy dependent resistance has been coined to describe a form of 
therapeutic resistance exhibited by CRC cells to 5-FU therapy, as it can be rapidly reversed 
following the molecular ablation of autophagy stimulating proteins or treatment with Chloroquine 
(which has anti-autophagy properties) 92. Despite its role in promoting cell survival, widespread 
autophagy that depletes a majority of cellular organelles can result in programmed cell death. 
Interestingly, there is evidence indicating that 5-FU treatment and a number of more novel 
experimental therapeutic agents, can induce autophagy-mediated cell death in human CRC cells, 
particularly when apoptotic mechanisms are compromised 93-95. Given the dual and antagonizing 
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roles of autophagy, it is currently being heavily investigated as a potential therapeutic target in 
cancer 96.  
1.4.3 Necroptosis 
While apoptosis remains the most widely studied and understood form of regulated cell 
death, ordered necrosis, dubbed as necroptosis, is now accepted as an important contributor to 
programmed cell death. Until relatively recently, necrosis was considered to be an unregulated, 
accidental and passive form of cell death. However, accumulating evidence indicating that cells 
can actively undergo a series of characteristic molecular and morphological changes in response 
to particular stimuli (such as TNF treatment) has led to the acknowledgment of necroptosis as a 
regulated form of death 97. Morphologically, necrotic cell death is contrasted from apoptosis by 
the occurrence of features such as the translucent cytoplasm, swelling of organelles, condensation 
of chromatin into irregular patches, the disintegration of the plasma membrane, and leakage of 
intracellular contents into the extracellular space. Additionally, unlike apoptosis, nuclei of 
necrotic cells remain intact, no membrane bound vesicle formation occurs, and eventually the cell 
undergoes total lysis 97.  
Although its existence is no longer intensely debated, the complete underlying 
mechanisms responsible for the onset of necroptosis in cells are yet to be elucidated. The onset 
of necroptosis is believed to involve a number of proteins, classified as either initiators or 
modulators/executioners. 98. Necroptosis can be initiated through the ligation of death receptors 
such as TNF-R1, FAS, and TRAIL-R, particularly when apoptosis is blocked through the 
inhibition of Caspases. The serine-threonine kinases, receptor interacting protein kinase-1 and 3 
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(RIPK-1, RIP-3), were found to play critical roles in the progression of necroptosis via the death 
receptor pathway 97. 
Necroptosis can also be instigated by the pathogen recognition receptor (PRR) family. 
Important members of the PPR family include the plasma membrane or endosome membrane-
associated Toll- like receptors, cytosolic NOD-like receptors, and retinoic acid-inducible gene I-
like receptors. These receptors are expressed on the surface of immune cells to detect pathogen-
associated particles, such as viral or bacterial nucleotides, lipoproteins, and peptidoglycans. Upon 
detection of viral or bacterial molecules by the PRR members, necrotic cell death may be induced 
97. Other more marginally studied initiators of necroptosis include reactive oxygen species, 
ubiquitin E3 ligases, certain deubiquitinating enzymes, mitochondrial and lysosomal membrane 
permeabilization, hyper-activation of PARP-1, and rapid lipid degradation that increases 
cytosolic calcium burden and alters mitochondrial dynamics 98.  
1.4.4 RIPK-1 at the crossroads of cell survival and cell death 
RIP serine/threonine kinase family members play crucial roles in detecting stress and in 
regulating cellular decisions regarding survival and death. RIP family members have structurally 
homologous N-terminal kinase domains, but possess vastly differing recruitment, and 
intermediate domains. The focus of the current work, RIPK-1, consists of a N-terminal serine-
threonine kinase domain and a homotypic interaction motif comprised of an intermediate domain 
and carboxy-terminal death domains. RIPK-1 contains several sites that may be post-
translationally modified, particularly Lys377 which can be ubiquitinated to allow interaction of 
RIPK-1 with a large number of proteins. The death domain of RIPK-1 is fundamental in the onset 
of cell death, while the intermediate domain participates in cell survival signaling via NF-κB. The 
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death domain of the RIPK1 interacts with death receptors such as TNF-R1 and Fas, as well as 
TRAIL1/2, TRADD, FADD, and Casapse-8, and is necessary for the induction of Caspase-8 
dependent apoptosis. The homotypic interaction motif of RIPK-1 facilitates the interaction with 
its sister necroptotic initiator, RIP-3 (Figure 10) 99.  
 
 
Figure 10. The structure of human RIPK-1 
Adapted from 99. 
 
 
RIPK-1 regulates cell survival and death through its participation in multiple cellular 
complexes described below. The binding of TNFα results in the ligation of the TNF-R1 death 
receptor, causing the formation of one of three complexes. Complex I mediates cell survival and 
involves the rapid association of the molecules TRADD (TNFR type 1 associated death domain 
protein), TRAF2/5 (TNFR associated factor 2/5), cIAP1/2 (cellular inhibitor of apoptosis 1/2) and 
the polyubiquitinated RIPK-1 at the plasma membrane. Ubiquitination of RIPK1 determines 
whether it participates in pro-survival or pro-death signaling. In complex I, RIPK-1 becomes 
polyubiquitinated (Lys63-linked chain type) in lipid rafts by TRAF-2, and acts as a docking site 
for the recruitment and activation of various components of the NF-κB survival pathway. This 
results in the subsequent induction of a number of anti-apoptotic proteins such as c-FLIP, cIAP1 
and cIAP2, as well as the activation of MAPKs such as p38, MAPK, JNK, and ERK. It is 
important to note however that kinase activity of RIPK-1 is not required for the activation of most 
MAPKs or NF-κB signaling. NF-κB survival signaling is negatively regulated via the depletion 
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of cIAP1 and cIAP2 proteins and the binding of the inhibitory proteins, A20 and Cyld to RIPK-
1. The Lys63-linked chain on RIPK-1 is edited by A20 and Cyld, switching its polyubiquitin 
moiety to the Lys48-linked form, thus, targeting RIPK-1 for degradation via the 26S proteasome 
complex, 99-103.   
 If the cellular environment is more conducive to death, RIPK-1 participates in molecular 
complexes that lead to apoptosis (Complex IIA) or necroptosis (Complex IIB). During the 
induction of death receptor mediated apoptosis, RIPK-1 was shown to be deubiquitinated by Cyld, 
and translocated to the death inducing signaling complex (DISC) known as complex IIA. This 
signaling moiety consisting of the molecules RIPK-1, FADD, TRADD and Caspase-8, rapidly 
activates Caspase driven apoptotic cell death.  Alternatively, this apoptotic-signaling complex 
may also be formed following the binding of the FAS ligand to the FAS death receptor. While 
the exact means of how RIPK-1 transitions from complex I to complex II remain ambiguous, 
deubiquitination is believed to play a crucial role in the dissociation of RIPK-1 from the pro-
survival complex I 99,101,104. For instance, the depletion of the deubiquitinase, Cyld, using siRNA 
methods was found to prevent the formation of complex II and inhibit both apoptosis and 
necroptosis 99,101.  Interestingly, apoptotic signaling is actively maintained by the prevention of 
survival and necroptotic signaling via the cleavage of RIPK-1 by Caspase-8 105. Complementary 
studies indicate that overexpression of the Caspase antagonist, FLIP, prevents the onset of 
apoptosis by failing to inhibit the survival and necroptotic signaling arms that are facilitated by 
RIPK-1 106.  
 The execution of necroptosis is arbitrated via the signaling Complex IIB, consisting of 
RIPK-1 and RIP-3.  Unlike its non-essential role in apoptosis, RIPK-1 is indispensable for the 
induction of programmed necroptosis 99,101,104.  Furthermore, elimination of RIPK-1 kinase 
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activity using the specific allosteric inhibitor, Necrostatin, maintained NF-κB survival signaling 
in cells, while prohibiting complex II formation and the onset of necroptosis, highlighting the 
fundamental role played by RIPK-1 in necroptotic cell death 98. RIP-3 has also recently emerged 
as a critical regulator of necroptosis, as knockdown of RIP-3 hindered the onset of TNFR-1 
mediated necroptosis in some cell types 107.  Importantly, necroptosis is primarily observed when 
Caspase activity is inhibited via the loss of Caspase-8/Fas-associated death domains, or through 
the inhibition of Caspase-8 enzymatic activity by the pan-Caspase inhibitor zVAD or viral 
proteins. In the absence of Caspase-8 activity, a functional DISC cannot form to induce apoptosis. 
RIPK-1 is therefore directed to form the necroptosome (RIPK-1 and RIP-3 complex). RIPK-1 
dimerization and autophosphorylation at Ser161 (which is believed to activate the kinase) are 
thought to play crucial roles in enabling necroptosis 105.  Following the assembly of complex IIB, 
RIP-3 phosphorylates RIPK-1. Although a substrate for RIPK-1 is yet to be definitively identified, 
the inhibition of RIP-3 phosphorylation at Ser199 when cells are treated with the RIPK-1 kinase 
inhibitor, Necrostatin, suggests that RIP-3 serves as a substrate for RIPK-1. Further research is 
however necessary to confirm the precise role of RIPK-1 kinase activity and its downstream 
targets. Given that necroptosis involves massive production of reactive oxygen species, it has 
been speculated that RIPK-1 directly targets the mitochondria. This notion is supported by data 
indicating that in TNF-stimulated cells, RIPK-1 translocates to the mitochondria. Despite the 
strides made over the last decade, the major gaps in our knowledge that remain regarding the 
onset of necroptotic cell death, underscore the need for extensive future research in this field 99,101.  
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Figure 11. Multiple RIPK-1 mediated signaling complexes are initated downstream of 
TNFR-1 stimulation.  
Adapted from 104. 
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2.0  CAUSES OF HGF GENE MUTAGENESIS IN HUMAN CRC 
2.1 ABSTRACT 
It is known that genomic instability, (both chromosomal and microsatellite instability) 
promote carcinogenesis by causing mutations in key growth regulatory genes, which 
consequently drive the tumorigenic process. The identity of these “so called driver genes” affected 
by genomic instability, however, has not yet been completely identified. Here, we report that 
microsatellite instability (MSI) provoked by DNA mismatch repair (MMR) deficiency causes 
deletion within an important repressor element in the HGF gene proximal promoter region. As 
this region consists of 30 deoxyadenosines, we have named it DATE (DeoxyAdenosine Tract 
Element]. We determined that DATE is polymorphic in nature, occurs in approximately 30% of 
sporadic human CRC, and significantly associates with the incidence of CRC, suggesting that 
DATE mutation plays a functional role in CRC pathogenesis. Furthermore, we noted that DATE 
truncation was significantly more prevalent in the normal tissues of African Americans in 
comparison to Caucasians. We postulated that this high incidence of germline DATE truncation 
may underlie the observed predisposition of African Americans to develop more aggressive forms 
of CRC and experience lower overall survival rates. We also noted that DATE truncation in tumor 
was a highly sensitive marker of MMR deficiency and MSI in human CRC. Collectively, our 
results revealed that in human CRC, HGF gene promoter is a target of mutagenesis provoked by 
defective MMR. Moreover, our findings encourage the adaptation of DATE as a highly sensitive 
marker for detecting MSI in the clinical arena, and warrant further investigation of the prognostic 
significance of DATE in human CRC.  
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2.2 INTRODUCTION 
Receptor tyrosine kinase (RTK) signaling is important in the regulation of a variety of 
processes including development, cell function and tissue maintenance. Despite these crucial 
roles, aberrant activation of RTK pathways has been implicated in the onset and progression of a 
variety of cancers. The HGF-Met signaling pathway is exemplary of this phenomenon. HGF is 
normally produced by stromal cell compartment of various tissues and elicits its effects by 
activating its cell surface receptor, Met 46,49. Binding of HGF to the Met receptor activates a 
number of complex signaling networks leading to cell growth, proliferation, and escape from cell 
death. Due to its critical role in a vast number of cellular processes, HGF-Met signaling pathway 
is tightly regulated through mechanisms such as receptor internalization, receptor degradation, 
and the maintenance of paracrine signaling. The loss of these regulatory measures is associated 
with a variety of human cancers 48. 
We recently showed that in a subset of human breast cancers, HGF gene promoter 
undergoes mutagenesis at a novel cis-acting regulatory element located approximately 700 bp 
from the basal promoter transcription start site. This element, which we have named DATE, 
consists of a poly-A tract of 30A, represses HGF gene transcription in epithelial cells by 
modulating chromatin structure and by regulating the binding of transcriptional repressors and 
activators to the HGF promoter 65.  Upon mutagenesis of DATE, repressor activity of the region 
is lost, leading to promoter activation and transcription of the HGF gene in epithelial cells. The 
molecular basis underlying DATE mutagenesis, and whether its mutation occurs in other human 
carcinomas remained unknown. The overall goal of this study was to address these issues.  
DNA mismatch repair (MMR) system is indispensable for maintaining genomic fidelity, 
particularly at microsatellite regions that are subject to frequent strand slippage during replication 
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76. MSI resulting from MMR deficiency is documented to contribute to many malignant 
conditions, including hereditary non-polyposis colorectal cancer (HNPCC, Lynch syndrome and 
its associated cancers), sporadic human colorectal carcinoma (CRC), as well as cancers of the 
endometrium, stomach, pancreas-biliary tract, small intestine, urothelium and the ovary 
76,82,108,109. As DATE consists of a repetitive tract of deoxyadenosines and resembles a 
microsatellite, we predicted that DATE mutagenesis could arise from MSI provoked by deficient 
MMR. We also hypothesized that that DATE truncation is a result of defective MMR and 
therefore could be observed in sporadic human CRC, which exhibits MMR defects and MSI in a 
significant patient subset.  
Our results indicated that the HGF promoter is indeed a target of genomic instability in 
CRC harboring MMR deficiency. We found that the frequency of DATE truncation significantly 
associated with the incidence of human CRC, suggesting that DATE mutagenesis plays a 
functional role in the onset and/or maintenance of the carcinogenic phenotype. DATE was noted 
to be polymorphic, and the incidence of DATE truncation in the normal population significantly 
differed between Caucasian and African American populations. Truncated DATE was also a 
highly sensitive indicator of MSI in CRC. Together, our results shed new lights on the potential 
molecular mechanisms of human CRC pathogenesis and support further development of DATE 
as a clinically relevant marker for detecting MSI in CRC.  
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2.3 MATERIALS AND METHODS 
CRC tissues and cell lines 
Archival human colon tumor tissues and paired normal adjacent tissues from 78 patients 
were obtained from Health Sciences Tissue Bank, University of Pittsburgh according to an 
approved IRB. Informed consent was obtained from all subjects prior to using tissue samples. 
These patients were of either Caucasian or an African American ethnic background as 
documented in Table 1. An Additional 50 human CRC tissues and corresponding adjacent normal 
tissues were purchased in the form of a tissue microarray (IMH-359) from IMGENEX. This 
particular cohort, consisting of patients of Asian ethnicity from Korea, were chosen as it was 
likely to be relatively homogenous in terms of genetic background. Additional information 
regarding the tissue microarray is provided in the following website: http://www.imgenex.com. 
All cell lines were purchased from American Type Culture Collection (ATCC) and cultured 
according to the supplier’s instructions. 
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 Case # Lymph node metastasis Gender
1 - M
2 + M
3 + F
4 - F
5 - M
6 - F
7 - F
8 - M
9 - F
10 + F
11 - M
12 + M
13 + M
14 - M
15 + F
16 + F
17 - M
18 - F
19 - F
20 - M
21 - F
22 - F
23 + M
24 - F
25 - M
26 + F
27 - M
28 - F
29 + F
30 - F
31 + M
32 - F
33 + M
34 + F
35 + F
36 - F
37 + M
38 - F
39 - M
40 - M
41 + F
42 - F
43 - M
44 - F
45 - F
46 - M
47 + F
48 - M
49 + M
50 + M
Type of tumor Tumor size (cm) Age  (yr) Race Tumor Normal Adjacent
          Length of DATE
AI 2.5 65 AA 25, 30 25, 30
AI 7 76 AA 29 29
AI 7 55 AA 30 30
AI 3 45 AA 19,30 19, 30
AI 11 75 AA 30 30
AI 5 85 AA 30 30
AI 1.5 85 AA
A 5.4 55 AA 24,30 24, 30
AI 8.5 65 AA 21,29 29
AI 4.6 65 CC 29 29
AI 2.5 45 AA 30 30
AI 5.2  N/A CC 30 30
A 4.5 55 CC 30 30
AI 8 75 CC 20, 30 30
AI N/A 86 CC 30 30
A 3.5 85 CC 22,29 29
AI 5 75 CC 30 30
A 3.5 75 CC 29 29
AI
A 4 75 CC 30 30
5 75 CC 31 31
A 3.7 75 CC 21, 30 30
A 5 85 CC 30 30
AI 5.5 85 AA 31 31
A
AI 9 75 CC 21, 30 30
7.2 45 CC 30 30
A 4 95 AA 30 30
AI 4.2 75 CC 28 28
AI 2 55 CC 30 30
AI 10 85 CC 18, 30 30
AI 3 85 CC 30 30
AI 3 75 CC 21, 30 21, 30
AI 13.5 45 CC 17, 22 30
A 3 65 CC 30 30
AI 3.5 45 CC 30 30
AI 4.5 65 CC 30 30
AI 8 55 AA 30 30
AI 4 85 CC 29 30
A 6 45 AA 30 30
AI 4 75 CC 30 30
AI 5.5 85 CC 30 30
A 6 85 CC 30 30
A 9.3 45  N/A 30 30
AI 5 85 CC 30 30
AI 5 75 AA 21, 30 30
AI 3 55 CC 29 29
A 7 65 CC 30 30
A 5.2 75 CC 30 30
AI 4 55  N/A 30 30
AI 4 65 CC 30 30
AI 4 61 CC 30 30
30 30
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Table 1: Patient demographics and genotype analysis of DATE in human CRC and 
corresponding adjacent normal tissues 
(A refers to adenocarcinoma, and AI refers to adenocarcinoma invasion.) 
 
Analysis of DATE and MSI status 
Genomic DNA was prepared from human cell lines and tissues using TRIzol reagent 
(Invitrogen) according to the manufacturer’s instructions.  The DATE region was amplified by 
PCR according to the protocol described in 65. The sequences of the fluorescent labeled (5’-FAM) 
primers used to amplify the DATE fragment are as follows:  forward primer 5’–
TATTTCGTGAGTTTGGCAGTTTGTG and reverse primer; 5’–
 Case # Lymph node metastasis Gender
51 + M
52 + M
53 + M
54 + M
55 - M
56 - M
57    N/A M
58 - M
59 + M
60 - M
61    N/A M
62    N/A M
63 - M
64 - M
65 + M
66 + M
67 + M
68 - M
69 + M
70 - M
71 - M
72    N/A M
73 - M
74  N/A  N/A
75  N/A  N/A
76  N/A  N/A
77  N/A  N/A
78  N/A  N/A
Race Tumor Normal Adjacent
AI 4.7 42 CC 29 29
Tumor size (cm) Age  (yr)
AI 6 58 CC 30 30
          Length of DATE
Type of tumor
AI 4.3 78 CC 18,21 30
AI 10 62 CC 27 27
AI 4 75 CC 28 28
AI 3 72 CC 28 28
AI 6 60 CC 28 28
AI 8 67 CC 30 30
AI 5.5 72 CC 29 29
AI 5 67 CC 28 28
AI 2.5 60 CC 30 30
AI 3 70 CC 30 30
AI 6 80 CC 28 28
AI 6 70 CC 27 27
AI 8 87 CC 30 30
AI 3.5 84 CC 30 30
AI 3.5 66 CC 30 30
AI 4 68 CC 30 30
A 3.5 86 CC 29 29
AI 3.5 62 CC 29 29
AI 3.5 78 CC 30 30
CC 28 28
A 2.5 79 CC 29 29
 N/A  N/A  N/A  N/A 30 30
 N/A  N/A  N/A  N/A 22,29 22,29
 N/A  N/A  N/A  N/A 30 30
 N/A  N/A  N/A  N/A 30 30
 N/A  N/A  N/A  N/A 19,25 30
AI 5 55
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AACAAAAGCACGCAGATTGTCAGATG which will yield a 121 bp DNA product.  For MSI 
determination, we used an assay kit from Promega Corporation which contain labeled primers for 
seven markers; five mononucleotide repeat markers: NR-21 SLC7A8; 103 bp), BAT-25 (c-kit; 
124 bp), BAT-26 (hMSH2; 120 bp), NR-24 (ZNF-2; 132 bp), and MONO-27 and two Penta 
repeats; Penta C and Penta D. The system allows amplification and detection of all markers in a 
single reaction.  All PCR products were separated by capillary electrophoresis using the ABI 
Prism 3100 Genetic Analyzer (Applied Biosystems). Data analysis was performed using the 
GeneScan Analysis software. MSI status was determined by assessing each of the 
mononucleotide markers for instability. Samples were classified as being either MSI-high (MSI-
H) if at least two of the five markers showed instability, MSI-low (MSI-L) if one marker showed 
instability, and MSI-stable (MSS), in the absence of instability. 
 
Immunohistochemical analysis of CRC tissues for MMR defects 
MLH1 and MSH2 immunostaining on human CRC tissue sections was performed by the 
Department of Pathology, Development Laboratory (University of Pittsburgh, School of 
Medicine) that performs this assay for clinical purposes. Tissues were classified as MMR 
proficient or deficient by observing for the presence of nuclear staining under light microscopy. 
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2.4 RESULTS 
2.4.1 An important regulatory region of the HGF gene promoter, DATE, undergoes 
deletion mutagenesis in human CRC 
We genotyped 78 cases of sporadic human CRC to detect the status of a novel HGF 
promoter regulatory region, DATE. We discovered that DATE undergoes deletion mutagenesis 
in the tumors, while remaining intact in the corresponding matched adjacent normal colon tissues, 
indicating that DATE is unstable in cancer. Representative genotyping results are depicted in 
Figure 12A. (DATE exhibiting loss of at least 2 deoxyadenosines was considered truncated, as 
per our findings regarding the functional consequences of DATE mutagenesis, described in 
Figure 15 and Table 5 in Section 3.4). We found DATE instability occurs at a frequency of 13% 
(10/78) in CRC.  Notably, we uncovered that DATE is polymorphic in nature, as 18% (14/78) of 
the CRC patients harbored the short DATE variant in both their tumor samples as well as in their 
corresponding normal tissues (Figure 12B, and Table 1). Thus, the overall incidence of the 
truncated DATE variant in CRC patients was observed to be 24/78 (31%).  We verified the 
polymorphic nature of DATE using genomic DNA isolated from peripheral blood lymphocytes 
of healthy individuals and found that the short DATE variant exists in the normal population 
(Figure 12C) at a frequency of 7.7% (46/592). We compared the frequency of occurrence of 
truncated DATE variant in CRC cases versus the normal population and found that DATE 
truncation significantly associates with the incidence of human CRC (p < 0.001, 2- tailed 
Fisher’s Exact test), suggesting that DATE mutagenesis may be playing a role in colon 
carcinogenesis and tumor cell survival/proliferation.  
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Figure 12. DATE is polymorphic in nature and undergoes deletion mutagenesis in human 
CRC 
(A) Representative genotyping from different human CRC cases showing DATE instability in 
tumors (T) as compared to the corresponding adjacent normal (N) tissues. A DATE wild-type 
case is also shown. Arrows indicate DATE length. (B) Representative genotyping results 
demonstrating that DATE is polymorphic in colorectal tissues. (C) Representative genotyping 
data of genomic DNA from blood lymphocytes of healthy individuals showing DATE is 
polymorphic in normal tissues and that the truncated DATE occurs in a heterozygous (N1, N2) 
or homozygous manner (N3, N4). 
 
We had previously shown that the incidence of the truncated DATE variant is significantly 
higher in the adjacent normal breast tissues of African Americans in comparison to that of 
Caucasians 65.  We found that the same trend occurred in the adjacent normal tissues of CRC 
patients: the short DATE variant occurred at a frequency of about 3% (15/473) in normal tissues 
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of Caucasians, compared to a frequency of 26% (31/119) in the normal tissues of African 
Americans. Statistical analysis indicated that African American subjects have a significantly 
higher incidence of DATE truncation in their adjacent normal colon tissues (p < 0.00001, 2- tailed 
Fisher’s Exact test).  
2.4.2 Defective mismatch repair is the underpinning cause of HGF promoter instability 
in human CRC 
The mismatch repair (MMR) system is indispensable for maintaining fidelity of DNA 
replication and genomic integrity, particularly at microsatellite regions 76. Microsatellite 
instability (MSI) resulting from MMR deficiency is documented to play important roles in a 
number of malignancies, including hereditary non-polyposis colorectal cancer (HNPCC, Lynch 
syndrome and its associated cancers) and sporadic colon cancer. 76,82,108,109. As DATE resembles 
a microsatellite, we hypothesized that its mutation could be due to genomic instability provoked 
by deficient MMR. Accordingly, we analyzed the CRC cases that exhibited truncated DATE 
variant for MSI using the well-established NCI-recommended MSI marker panel, which consists 
of five mononucleotide markers, NR-21, NR-24, BAT25, BAT26, MONO27. Samples were 
classified as microsatellite instability high (MSI-H) if at least two of the five markers showed 
instability, microsatellite instability high (MSI-L), if one marker showed instability, and 
microsatellite stable (MSS), in the absence of instability. The results revealed that nearly all of 
the cases with unstable DATE in the tumor (as compared to normal adjacent tissue) exhibited the 
MSI-H phenotype (Figure 13A, and Table 2), indicating a strong correlation between DATE 
mutagenesis and MSI.  Interestingly however, two CRC cases that harbored mutant DATE were 
classified as MSS according to the MSI markers panel. These cases are discussed below. 
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The underlying cause of MSI is known to be MMR deficiency, and is characterized by an 
increased frequency of mismatches and alterations (deletion of mononucleotide repeats and 
deletion or expansion of oligonucleotide repeat regions) 76. In human CRC, MMR deficiency is 
most often due to the loss-of-function of “caretaker” genes, MLH1 or MSH2, (which govern the 
process of DNA mismatch repair during replication). MLH1 or MSH2 expression is routinely 
assessed in the clinical arena by IHC. Therefore, we performed IHC on our CRC samples to assess 
for the expression status of these MMR proteins. Our data clearly showed that all DATE unstable 
tumors have deficient MLH1 or MSH2 expression, while DATE stable tumors have robust 
expression of both proteins (Figure 13B).  
Of note, the above-mentioned two DATE mutant tumor cases that were classified as 
microsatellite stable according to the MSI marker panel, interestingly exhibited defective MLH1 
protein expression as detected by IHC (Figure 13C). These findings suggested that DATE could 
serve as a sensitive marker of MSI, even in cases where standard MSI markers fail to detect 
instability.  
Additionally, we also examined the MSI and DATE status of several human breast cancer 
cases and noted that those with a MSI-H phenotype expectedly harbored DATE truncations, 
further indicating that DATE instability in cancer likely results from defective MMR (Figure 
13D).  
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Table 2: MSI status in human CRC and corresponding adjacent normal tissues in patients  
harboring truncated DATE 
 
 
 
 
Case # Tissue type NR21 BAT26 BAT25 NR24 MONO27 DATE status MSI status
Tumor 101  115  124  131  151  25,30
2 Normal 101 115 124 131 151  25,30
Tumor 101  104,115  123,127  131  153  19,30
Normal 101 104,115 124,127 131 153  19,30
Tumor  93,100  101,105  119,123  126  143,151  21,29
Normal 101 104,115 123 131 152 29
Tumor 101  115 124 131 153  24,30
Normal 101 115 124 131 153  24,30
Tumor   91,96 103,115 116,125 128,131 147,151 20,30
Normal 96,101 115 125 131 152 30
Tumor 101 115  125  132  152  22,29
Normal 101 115 125 132 152 29
Tumor  92,101  105,115  119,124  131  153  21,30
Normal 101 115 124 131 143 30
Tumor 101 115 125 131 153 21,30
Normal 101 115 125 131 153 30
Tumor 94,101 103,114 124 131 144,152 18,30
Normal 101 114 124 131 152 30
Tumor 95,99 104,115 121,125 132 143,153 21,30
Normal 101 115 125 132 153 21,30
Tumor 94 106 114 123 146 17,22
Normal 101 115 124 131 152 30
Tumor 101 104 120 132 146,152 21,30
Normal 101 114 124 132 152 30
Tumor 93,101 105,115 124 131 139,146 18,21
Normal 101 115 124 131 152 30
Tumor 92,101 104,115 115,119 129 141,151 19,25
Normal 101 115 124 132 152 30
8  MSS
 MSS
3  MSS
7 MSI-H
15 MSI-H
17  MSS
21 MSI-H
23 MSS
28 MSI-H
30 MSI-H
74  MSI-H
33 MSI-H
45 MSI-H
52 MSI-H
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Figure 13. DATE mutagenesis results from genomic instability provoked by defective DNA 
Mismatch Repair (MMR) 
(A) MSI status of DATE mutant CRC cases and their corresponding normal adjacent counterparts. 
The numbers 1-5 refer to the MSI markers, NR-21, BAT26, BAT25, NR-24, and MONO27, 
respectively. The arrows indicate the presence of instability. (B) Immunohistostaining 
documenting the absence of MLH1 or MSH2 in tumors having mutant DATE. A representative 
case that is MSI-stable, MMR proficient, harboring wild-type DATE (30A, 30A) is also 
presented. (C) DATE alteration is detectable in the tumor as compared to adjacent normal tissues, 
while other markers are intact and exhibit no alterations. Immunostaining corresponding to the 
same tumor is shown documenting that tumor with unstable DATE is indeed MMR deficient, as 
it lacks MLH1. (D) Representative electropherograms showing the status of MSI markers and 
DATE of a breast cancer case exhibiting instability and DATE truncation in tumor.  
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Our data has indicated that DATE mutagenesis occurs in CRC patient tissues and is likely 
provoked by defective MMR. For ease of further characterization of this phenomenon, we decided 
to incorporate human CRC cell lines in to our studies. Therefore, next we assessed the MSI and 
DATE status of human cancer cell lines to verify that genomic instability facilitated by defective 
MMR correlates with DATE mutagenesis.  
We confirmed that human CRC cell lines with known MMR defects exhibit the MSI-H 
phenotype (Figure 14A). Genotyping for DATE revealed that human CRC cell lines with MMR 
deficiency and MSI have truncated DATE: HCT116 (18A, 21A), HCT-15 (23A), RKO (18A), 
SW-48 (18A, 23A), LoVo (17A). In contrast, wild-type DATE was observed in the two MSS and 
MMR proficient cell lines, HT-29 (30A) and SW-620 (30A) (Figure 14B). These findings were 
verified through DNA sequencing (Figure 14C). We also assessed the MSI status of other human 
cell cancer lines that we discovered to have truncated DATE; namely C33A, a cervical carcinoma 
cells line which has DATE with 12A and Jurkat cells, a lymphoma cell line, which has a DATE 
with 16A.  Our data on DATE and MSI in human cell lines are summarized in Table 3. 
 
Table 3: Human cancer cell lines known to have MMR deficiency and MSI also exhibit 
DATE instability  
 
 
Cell line NR-21 BAT-26 BAT-25 NR-24 MONO-27 DATE
Cancer 
Type
MSI-status  
   MMR 
status
HCT116 94 103 118 122 143 18A, 21A Colon MSI-H Deficient
RKO 87 104 114 125 140 18A Colon MSI-H Deficient
LOVO 90,96 104 115,124 127, 131 146 17A Colon MSI-H Deficient
SW-48 92 102 115 128 140,145 18A,23A Colon MSI-H Deficient
SW620 101 115 124 131 152 30A Colon MSS Proficient
Proficient
C33A 93 104 112,118 123 143 14A Cervical MSI-H Deficient
HELA 101 114 124 131 153 30A Cervical MSS Proficient
JURKAT 94 109 119 129 147 16A Leukemia MSI-H Deficient
MSSHT-29 101 115 125 132 152 30A Colon
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Figure 14. Human CRC cell lines with microsatellite instability harbor mutant DATE 
(A) Representative electropherograms depicting the status of MSI markers in six human CRC cell 
lines. MSI status was assessed using a MSI marker panel where numbers 1-7 refer to NR-21, 
BAT26, BAT25, NR-24, MONO27, BAT-26, and Penta-D, respectively. The arrows indicate the 
presence of instability at a given marker. Samples were classified as MSI-H if at least two of the 
five markers showed instability, MSI-L, if one marker showed instability, and MSS, in the 
absence of instability. (B) Representative electropherograms depicting the status of DATE in the 
human CRC cell lines shown in (A), indicating that cell lines with MSI-H phenotype exhibit 
unstable DATE. (C) Representative DNA sequencing results confirming the length of the wild-
type DATE in HT-29 (30A) and mutant DATE in HCT116 (18A). 
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2.5 DISCUSSION 
Tumorigenesis has long been described as a multistep process in which sequential 
activation of proto-oncogenes and inactivation of tumor suppressors occur within a genetically 
unstable background. This view of cancer as being the result of sequential abnormal molecular 
events, initially led researchers to imagine that overarching, rather than targeted therapies are 
likely to have the greatest therapeutic potential. However, it is now becoming clear that the 
oncogenic phenotype is far more complex than the simple sum of all abnormal molecular events. 
Instead, we are now understanding that alterations in oncogenes and tumor suppressors that are 
capable of regulating multiple cellular signaling networks can serve as the single-handed 
“drivers” of cancer 110. HGF-Met is one such “driver” which induces complex signaling systems, 
leading to cell growth, proliferation, escape from cell death, and tumorigenesis. We uncovered 
that the HGF promoter undergoes deletion mutagenesis in human CRC. Our work showed that 
HGF promoter mutation significantly associates with the incidence of CRC, suggesting that it 
aids in the onset and/or the maintenance of the malignant phenotype. Our data indicating that 
DATE truncation occurs in both human breast and CRC also suggested that HGF promoter 
mutagenesis may be a ubiquitous phenomenon that is worth investigating in other malignancies 
as well.  
Nucleotide repeat microsatellite regions such as DATE are prone to polymerase slippage 
during DNA replication and are therefore particularly susceptible to the accumulation of 
mutations. When a mismatch occurs in a coding region of a key regulatory gene in a MMR 
deficient background, it can provide an abnormal growth advantage and eventually promote 
carcinogenesis 76. Accumulation of genomic and epigenetic alterations facilitated by the loss of 
genomic stability has long been known contribute to tumorigenesis of sporadic and familial forms 
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of CRC. MSI caused by aberrant CpG methylation of MLH1, or point mutations in MLH1, MSH2 
or other MMR pathway genes, are noted to play crucial roles in the onset and progression of 
approximately 20% of sporadic CRC 82. In our studies, we noted that DATE consisted of a poly-
A-tract resembling a microsatellite region. Further investigations revealed that DATE 
mutagenesis is a manifestation of underlying MSI that occurs as a result of defective MMR. Given 
that HGF is a highly important regulator of multiple cellular processes, occurrence of DATE 
truncation in a MMR deficient background is expected to provide a significant growth advantage 
to those cells harboring the mutation (Data supporting this view is shown in Section 3).  
Single sequence repeats of poly-A tracts are abundant throughout the human genome and 
constitute parts of the coding sequence or regulatory elements of many genes 111,112. The hyper-
mutability of poly-A tracts in CRC was highlighted in a study of germline mutations at the 
polymorphic BAT-40 locus, which indicated that mutations in BAT-40 occur in 7% of MMR 
deficient CRC 113. In a separate study, a poly-A repeat consisting of 13A located in the 3' 
untranslated region (3' UTR) of EGFR was found to be commonly mutated in MMR deficient, 
colonic and endometrial carcinomas, leading to increased EGFR mRNA stability 114. In 
congruence with these findings, our work further attests to the hyper-mutability of poly-A tracts 
and their importance in colorectal tumorigenesis. Long poly-A tracts (approximately 30-70A) 
have previously been documented to act in a transcriptional repressive manner by readily 
wrapping around histones and effectively reducing accessibility of transcription factors to 
promoters. In contrast, incorporation of shorter adenosine tracts (i.e.16A, 17A) into nucleosomes 
were shown to generate a wide and shallow major groove on DNA by disrupting histone-DNA 
interactions, resulting in increased transcription factor accessibility 111,115,116. Our earlier 
investigations in human breast cancer revealed that shortening of DATE causes chromatin 
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loosening, repressor binding loss, and promotes the binding of transcriptional enhancers, leading 
to the activation of the HGF promoter. In light of these findings and the existing body of results 
regarding the importance of poly-A tracts in transcriptional regulation, we expect that DATE 
mutagenesis in CRC would result in similar promoter dysregulation and activation of HGF 
transcription. Our findings regarding the consequences of DATE mutation in CRC, (discussed in 
detail in Section 3), strongly supports this hypothesis.  
Our work also uncovered that DATE is polymorphic in nature, i.e. germline DATE wild-
type and truncated variants are observed in the normal population. Interestingly, stratification of 
our data by ethnicity revealed that the incidence of the truncated DATE variant was greater in the 
normal tissues of African Americans in comparison to their Caucasian counterparts.  Research 
indicates that African Americans develop CRC at a younger age, have a higher incidence of 
cancer, show increased mortality and worse prognosis than Caucasians of the same disease stages. 
Genetic factors are reported, at least in part, to contribute to this observed ethnic discrepancy 117. 
It is possible that the significantly increased incidence of DATE truncation observed in the normal 
tissues of African Americans plays a role in predisposing this population to develop more 
aggressive forms of CRC at earlier ages and at a greater frequency. While our sample size of 
African Americans was relatively small, the observed trend may be worth further examination 
through large-scale studies to conclusively determine whether DATE could be used in the clinical 
arena as a predictive marker of CRC predisposition and disease prognosis. 
Over the last two decades there has been a heavy emphasis on the development of 
biomarkers to accurately forecast CRC patient prognosis and to refine predictions regarding 
patient response to therapy. Multiple studies have indicated that the incidence of MSI can be used 
as prognostic biomarker, predictive of whether patients will respond to adjuvant chemotherapy. 
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MSI-H patients, particularly those harboring stage II disease, are believed to gain little benefit 
from 5-FU therapy. Therefore, CRC patients are generally assessed for MSI to determine whether 
alternative treatment protocols are needed 82. The incidence of MSI is currently evaluated using 
a NCI recommended “gold standard” panel consisting of five mononucleotides and two penta-
nucleotide repeats 76. While these markers have shown promise in detecting MSI and in 
identifying adjuvant therapy resistant CRC subsets, development of more sensitive and reliable 
biomarkers will increase predictive precision and improve patient outcomes. We found that in 
human CRC tissues, DATE truncation accurately predicted MMR defects and high-MSI 100% of 
the time, even in situations where the above mentioned “gold standard” markers failed to detect 
instability. This data implied that DATE is a highly sensitive indicator of genomic instability. In 
light of the recent focus on establishing clinically applicable cancer biomarkers, our data 
encourages the development of DATE as a sensitive marker for the identification of MSI in CRC. 
Furthermore, our findings warrant the exploration of DATE as a potential predictive marker of 
CRC patient prognosis and therapeutic response.  
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3.0  CONSEQUENCES OF HGF GENE MUTAGENESIS IN HUMAN CRC 
3.1 ABSTRACT 
Aberrant HGF expression is believed to drive the malignant transformation of several 
human cancers, but the molecular bases of dysregulated HGF expression has largely remained 
unknown. We discovered that the HGF promoter undergoes mutagenesis at an important 
upstream regulatory region, dubbed DATE, leading to the activation of HGF transcription in 
human CRC cells.  In the normal colon epithelium, HGF is generally silenced, and paracrine 
signaling is maintained. HGF promoter mutation disrupts this signaling dynamic, resulting in the 
formation of an HGF-Met autocrine loop in CRC cells. Functional studies, including somatic gene 
targeting of endogenous wild-type DATE in human CRC cell lines, revealed that DATE 
mutagenesis is sufficient to activate HGF gene transcription. Furthermore, we demonstrated that 
HGF-Met signaling fosters tumor cell growth by conferring resistance to both forms of cell death, 
namely apoptosis and necroptosis. We show for the first time that growth factor signaling can 
directly impact RIPK-1, a key mediator of necroptosis. This is achieved via tyrosine 
phosphorylation of RIPK-1 by activated Met, resulting in the inhibition of RIPK-1 kinase activity. 
We also discovered that Met activation causes RIPK-1 recruitment to plasma membrane, 
polyubiquitination (Lys-48 linked chain) and its subsequent proteasomal degradation. Moreover, 
we found that aberrant HGF expression in tumor tissues significantly correlates with low RIPK-
1 and with poor clinical prognosis.  Collectively, our results shed important mechanistic insights 
into the molecular mechanisms of human colon carcinogenesis, and encourage further study of 
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HGF-Met as a viable therapeutic target in CRC, especially in those subsets harboring HGF gene 
mutations. 
 
3.2 INTRODUCTION 
The HGF-Met signaling axis is a key growth regulator known for its role in inducing 
complex signaling networks leading to cell survival, growth, and proliferation. When aberrantly 
activated, however, HGF-Met signaling can promote tumorigenesis 48. HGF is normally produced 
by the stromal cell compartment of various tissues and elicits its effects by activating its cell 
surface receptor, Met, which is highly expressed in epithelial cells 46,49. HGF gene transcription 
is silenced in normal epithelial cells and its expression in stromal cells is tightly regulated by a 
variety of signaling molecules, including hormones like estrogen, and cytokines such as TNFα, 
and IL-1. Although the detailed molecular mechanisms governing cell type specific expression 
of HGF remain obscure to some degree, we now understand that repression of HGF transcription 
in epithelial cells is controlled by multiple cis-acting, upstream regulatory elements, particularly 
those located within 1 kb upstream from the transcription start site of the HGF promoter 57-59,63,65. 
We previously showed that the HGF gene promoter undergoes mutagenesis (at DATE) in a subset 
of human breast carcinomas, causing promoter activation.  The resultant formation of an HGF-
Met autocrine circuit was observed to contribute to breast tumorigenesis. In the present work, we 
uncovered that DATE is also a target of deletion mutagenesis in human CRC as a result of 
defective MMR and underlying microsatellite instability.  Given the bleak prognosis of human 
CRC, novel therapeutic targets are direly needed.  Our work (shown in Section 2) showed that 
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DATE mutation significantly associates with the incidence of human CRC, and thus, we 
hypothesized that it has functional consequences on HGF promoter activity, and that harboring 
truncated DATE promotes cancer cell survival, proliferation, and escape from death.  
Genetic alterations in growth regulatory genes such as HGF and MET are recognized to 
play a key role in tumorigenesis and the maintenance of the malignant phenotype 49,73. 
Mutagenesis of these fundamental regulator genes makes greater contributions towards the onset 
and the maintenance of cancer, leading to an occurrence known as “oncogenic addiction”. This 
phenomenon refers to the fact that despite harboring multiple molecular alternations, cancer cells 
may be directly dependent on a single oncogenic pathway for cell survival and proliferation 118. 
Targeting these fundamental players has been shown to be extremely beneficial in the treatment 
of a variety of cancer types 68. For instance, transient inactivation of transforming oncogenes such 
as Ras, Myc, BCR-Abl in malignant tumors with complex genetic backgrounds has resulted in 
the reversal of the transformed phenotype. Clinical examples of successful targeting of oncogenes 
include neutralizing antibodies against the HER-2 receptor in metastatic breast cancer and the use 
of Gleevec in chronic myelogenous leukemia and gastrointestinal stromal tumors 110. 
Furthermore, in experimentally generated tumors in mice involving multiple genetic events, the 
intermittent inactivation of the oncogene alone, induced tumor regression 119. 
Given the high incidence of DATE mutation observed in CRC, and the well acknowledged 
role of HGF-Met in cancer, we postulated that the HGF-Met signaling axis serves as an oncogenic 
driver in a subset of CRC and presents a novel therapeutic target to be utilized in the arena of 
personalized medicine. We found that DATE mutation is sufficient to activate the HGF promoter, 
and leads to the creation of an HGF-Met autocrine loop in the CRC cells, making them growth 
factor autonomous. Furthermore, we showed that DATE mutation promotes oncogenic addiction 
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of CRC cells to HGF-Met signaling, by stimulating cell survival and resistance to cell death. Of 
note, our results indicated that HGF-Met signaling inhibits necroptosis via phosphorylation-
mediated inactivation and down regulation of the key necroptosis initiator protein, RIPK-1. 
Harboring mutant DATE in tumor was found to correlate with HGF up regulation, RIPK-1 down 
regulation, significantly larger tumor size, and poor patient prognosis in sporadic human CRC. 
3.3 MATERIALS AND METHODS 
CRC tissues and cell lines 
Archival human colon tumor tissues and paired normal adjacent tissues from 78 patients were 
obtained. Analysis of DATE status was performed using genomic DNA from human cell lines 
and tissues. All described cell lines were purchased from American Type Culture Collection 
(ATCC) and cultured according to the supplier’s instructions. (Refer to Section 2.3 for further 
details regarding these procedures).  
 
HGF and MET mRNA expression analyses 
HGF and MET mRNA expression were detected by RT-PCR by reverse transcribing total 
RNA using AMV Reverse Transcriptase (Promega) and Random Primer (Roche Applied 
Sciences) in a volume of 40 μl according to standard procedures. The forward primer for HGF 
was from exon 11 (5′-CTCATTCCTTGGGATTATTGCCC), and the reverse primer was from 
exon 14 (5′-CCTTTATCAATGCTCCGCAG). The reverse transcriptase product was used to 
carry out PCR analysis for 40 cycles using the ABI Prism 7000 Sequence Detection System with 
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reagents and primers specific to human HGF supplied by Applied Biosystems. 
Diethylpyrocarbonate-treated water was also included as a negative control for contamination. 
 
Transient transfections and luciferase assays 
Tumor-derived human HGF promoter regions (1.1 kb; –1037 to +56) containing wild-
type or DATE of different sizes (30A, 29A, 28A, 27A, 26 A, 25A, and 20A were cloned by PCR 
and sequence verified) were inserted upstream of the luciferase reporter gene in the pGL2-basic 
vector (Promega lengths: pHGF30A-Luc, pHGF29A-Luc, pHGF28A-Luc, pHGF27A-Luc, 
pHGF26A-Luc, pHGF25A-Luc, and pHGF20A-Luc. Human CRC cell lines and fibroblast (NIH-
3T3) cells were seeded in 96-well culture plates (3 × 104 cells/well) and cultured for 24 hours 
before transfection. The renilla luciferase–encoding plasmid, pRL-TK, (Promega Corp) and 
pHGF-Luc plasmids were transiently co-transfected into cells using Lipofectamine 2000 
(Invitrogen). Expression of renilla luciferase activity was used as an internal standard for 
transfection efficiency. The promoter activities were measured using the Dual Luciferase 
Reporter Assay System (Promega). After 24 hours, transfected cells were collected and luciferase 
activity was measured according to manufactures instructions using the luminometer function of 
Synergy HT Multi-Mode Microplate Reader (Biotek).  
 
Construction of gene targeting vectors  
Genomic DNA from human C33A cell lines (which has the shortest DATE that we have 
observed [DATE with 12A] and highly expresses HGF gene) was used as a template for 
generating the left and right homology arms for gene targeting by PCR. The left homology arm 
(LHA) is 1.14 kb. LHA forward primer is called P1 and contains a NotI site. The reverse primer 
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is named P2, and contains the linker A sequence. The right homology arm of 0.8 kb consists of 
the forward primer, P3, which contains a linker B sequence, and the reverse primer is P4, which 
contains a NotI site (Table 4 and Figure 17A). The two arms were subcloned into the PCR 2.1 
vector in order to verify that the sequence containing the mutated DATE of 12A. The two arms 
were then amplified by PCR. The forward primer, PN1, and the reverse primer, PN2, were used 
for amplifying LHA.  The forward primer, PN3, and the reverse primer, PN4, were used for 
amplifying RHA. Two enzyme sites were introduced into these primers as specified in Table 4. 
The pNeDaKO fragment was generated by PCR using primers PN5 and PN6. The pNeDaKO-
Neo vector (2.2 kb) was used as a template, which contained Neo gene driven by 
phosphoglycerate kinase (PGK) promoter, a zeomycin resistance gene (Zeo) driven by EM7 
prokaryotic promoter, loxp sites, and the linkers A and B. The LHA, RHA and pNeDaKO 
fragments were re-subcloned into pAAV-MCS and the target vector, pAAV-Neo-HGF, was 
generated as depicted in Figure 17A.  
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Table 4: Primer sequences used in somatic gene targeting of wild-type DATE  
Primer sequences used in the Construction of pAAV-Neo-HGF targeting vector for somatic gene 
targeting to replace the endogenous wild-type DATE with a truncated DATE in the HT-29 CRC 
cell line. Underlined sequences represent restriction enzyme sites or linker sequences.  
 
Somatic gene targeting in human CRC HT-29 cells 
The rAAV targeting vector was packaged by mixing pAAV-Neo-mHGF with pAAV-RC 
and pHelper plasmids from AAV Helper-Free System (Stratagene), and transfected into HEK 293 
cells (ATCC) using Lipofectamine (Invitrogen) according to the manufacturer’s instructions.  
HT-29 cells were grown in a 100 cm2 flask until 60-80% confluence was reached, washed with 
HBS, and 500 ul of HEK 293- rAAV lysate and 4.5 ml of the appropriate growth media was 
added to the flask. The virus was allowed to infect the cells at 37C for 2-3 hours, following 
which, the cells were allowed to grow in normal media for 48 hours. The cells were harvested by 
trypsinization and distributed into twelve 96- well plates with media containing G418 (0.5 mg/ml, 
Invitrogen). Genomic DNA was extracted from colonies grown in 96-well plates, and the 
targeting events were screened by PCR using the forward primer (FP) that was situated outside 
of the LHA, and the reverse primer that was situated in PGK region. The DATE mutation was 
verified by PCR using primers situated in HGF promoter region. The presence of truncated and 
Name                                      Sequence
P1:         5’-ATACATACGCGGCCGCATGGACAATGACTGTTTCTTGGAC-3’
P2:         5’-GCTCCAGCTTTTGTTCCCTTTAGAAGGAATAGGGAAGGTTAGCAGGAG-3’
P3:         5’-CGCCCTATAGTGAGTCGTATTACTTTCTGAACTCAGTATGTAGTATAGG-3’
P4:         5’-ATACATACGCGGCCGCATTTGTTCCCACTCTTTTATTCCC-3’
PN1:      5’- ATACATACGCGGCCGCATGGACAATGACTGTTTC-3’ 
PN2:      5’-GGAATTCCAAGGAATAGGGAAGGTTAGCAGGAG-3’   
PN3:      5’- GGAATTCCTTTCTGAACTCAGTATGTAGTATAGG-3’ 
PN4:      5’- GGGGTACCCCATACATACGCGGCCGCATTTGTTC-3’ 
PN5:      5’-GGAATTCCACCGCGGATAACTTC-3’  
PN6:      5’-GGAATTCCACTCACTATAGGGCG-3’
FP:        5’-ATTTCCGGTGAAAGTCAGTCC-3’
RP:        5’-CTGACTAGGGGAGGAGTAGAAG-3’        
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wild-type DATE fragment was detected on 15% denaturing polyacrylamide gel containing 8M 
urea and verified by DNA sequencing.  
 
Preparation of protein extracts and Immunoblotting 
Whole cells protein lysates were prepared from cells plated into 6-well plates and treated 
for various time points, by scraping cells into RIPA buffer containing protease and phosphatase 
inhibitors. Protein extracts from tissues were prepared by homogenizing 100 mg-500 mg of 
human colorectal tumors or normal adjacent control tissues in RIPA buffer containing protease 
and phosphatase inhibitors (100 μL/100 mg). Cell lysates were cleared by centrifuging at 
11,000 g for 20 minutes and protein concentrations were determined using a BCA assay. Sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed with the cleared 
protein lysates, and proteins were transferred to nitrocellulose membranes. Following blocking 
for one hour at room temperature in 5% BSA (for phospho-proteins) or 5% milk diluted in Tris-
Buffered Saline with 0.1% Tween 20 (TBST), membranes were incubated with primary 
antibodies diluted in 5% BSA specific to human HGF (AF-294-NA and AB-294-NA) at 1:1000 
dilution (R&D Systems), Met (C-28) at 1:250 dilution, Ubiquitin at 1:1000 dilution (Santa Cruz 
Biotechnology Inc.), RIPK-1 at 1:1000 dilution (Sigma Aldrich), HMGB1 at 1:1000 dilution 
(Abcam), Actin at 1:4000 dilution (Millipore), phosphorylated Met Tyr 1234/1235, 
phosphorylated-Akt, total Akt, phosphorylated Erk, total Erk, PARP, K63-linkage Specific 
Polyubiquitin, and K48-linkage Specific Polyubiquitin  (all at 1:1000, Cell Signaling Inc.) 
overnight at 4°C. After washing with TBST, membranes were incubated with secondary 
antibodies for two hours at room temperature, and proteins were visualized using enhanced 
chemiluminescence detection system (Amersham Pharmacia Biotech). 
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Immunohistochemistry and immunofluorescence 
 Colorectal cancer tissue sections were deparaffinized in xylene, dehydrated in ethanol, 
and incubated with polyclonal antibodies specific to human HGF (AF-294-NA) at 1:50 dilution 
(R&D Systems), Met at 1:100 dilution (C-28; Santa Cruz Biotechnology Inc), and RIPK-1 at 
1:500 dilution (Sigma Aldrich) overnight at 4°C. Non-immune IgG primary antibody was used 
as a negative control. Tissues were then incubated with HRP-conjugated secondary antibody for 
30 minutes at room temperature. ABC kit from Vector Laboratories was used to develop the 
antibody staining.  Relative percent area and percent intensity of immunostaining were then 
quantified using Image J software (National Institutes of Health) in accordance with the 
recommended guidelines. In summary, threshold analysis was performed on the images by first 
assessing the total area staining, followed by the area of tissue that is positive for a particular 
stain. These two values were then used to determine the percent area and intensity of tissue 
staining. At least three high quality images (obtained using light microscopy) of random fields 
totaling more than 1,000 cells were quantified per each patient case.  The percentage of total area 
stained and the relative intensity of staining were determined and expressed as bar graphs. HGF 
and RIPK-1 staining was classified into two groups of low and high by using the median value as 
a “cutoff”, according to the methods previously described in 120. For immunofluorescence staining 
for HGF, Met and RIPK-1, cells were grown on coverslips and fixed with methanol, then 
incubated with primary antibody (HGF antibody from R&D), Met (c-28 Santa Cruz and L6E7, 
Cell Signaling technology and RIPK-1 also from Cell Signaling technology) at 1:50-100 dilution 
overnight at 4°C. Cells were washed, and then incubated with biotinylated secondary antibody 
(Vector Laboratories), indocarbocyanine Cy2 (goat, green 1:100), or Cy3 (rabbit, red 1:200) for 
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30 minutes at room temperature. Slides were rinsed with PBST and the nuclei were stained with 
VECTASHIELD Mounting Medium with DAPI  (Vector Laboratories).  
 
Cell growth/viability assays 
Human CRC cell lines were plated at 5,000 cells/well in 96-well plates and allowed to 
grow for 24 hours. For drug treatment experiments, cells were the serum starved overnight and 
treated with 0-20 μM SU11274 (Sigma Aldrich) or 50 μM Necrostatin (Sigma Aldrich) where 
indicated. All drugs were prepared by dissolving the powder form in DMSO; therefore DMSO 
was used as the negative control. For HGF neutralizing antibody (R&D Systems) treatment, cells 
were serum starved overnight and treated with 10 ng/mL of neutralizing antibody or control 
normal goat IgG diluted in sterile PBS. For active HGF ligand treatment, cells plated at 5,000 
cells/well were allowed to grow for 24 hours and serum starved for 48 hours in order to remove 
the growth and survival effects induced by serum. Cells were then treated with lyophilized active 
recombinant HGF (R&D Systems) at 50 ng/mL diluted in sterile PBS. Cell growth and viability 
were measured using MTT (Sigma Aldrich) assays at the indicated time-points post-treatment. 
For MTT assays, the MTT reagent, Thiazolyl Blue Tetrazolium Bromide (Sigma Aldrich) was 
dissolved in sterile PBS at a concentration of 1 mg/mL. Media was removed from 96-well plates 
and 100 μL of MTT solution was added to each well. Cells were allowed to incubate in MTT 
reagent for 1 hour at 37°C and the blue product in cells was solubilized by adding 100 μL 40 mM 
HCL in isopropanol. The absorbance was quantified using Synergy HT Multi-Mode Microplate 
Reader at a wavelength of 590 nm with a reference filter of 620 nm. Results were averaged 
between three replicates.  
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In-Situ Caspase-3 assay 
 To assess Caspase 3/7 mediated apoptosis in live cells, CellEvent® Caspase-3 Detection 
Reagent (Invitrogen) was diluted in media, and added to cells in 96-well plates at a concentration 
of 8 μM, simultaneously with SU11274. Plates were incubated at 37°C for varying periods of 
time. The fluorescence emission of the bound dye was read using a microplate reader at 
excitation/emission maxima of 502/530. Apoptotic cells were visualized using a fluorescent 
microscope. 
 
Determination of RIPK-1 tyrosine phosphorylation site.   
Recombinant pure active human RIPK-1 (Creative Biomart) was incubated with pure 
active human Met kinase (Invitrogen) in kinase buffer for 30 minutes, samples were subjected to 
SDS-PAGE, and portions of the gel were analyzed by western blot, whereas the remaining portion 
of the gel was subjected to Coomassie blue staining. The band corresponding to RIPK-1 was cut 
out and sent to the Proteomic Facility of Ohio State University (Web Address: www.ccic.ohio-
state.edu/MS) without revealing the identity of the sample. They correctly identified it as human 
RIPK-1 and determined that Tyr384 is phosphorylated.  
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3.4 RESULTS 
3.4.1 DATE mutation reactivates the silenced HGF promoter  
Long poly-A tracts are documented to contribute to transcription repression while 
shortening of these regions disrupt histone-DNA interactions, increase transcription factor 
accessibility, and facilitate promoter activation 111-113,115,116.  Our data up to this point have shown 
that that the DATE poly-A tract undergoes deletion mutagenesis in human CRC as a result of 
defective MMR, and that DATE mutation significantly associates with the incidence of cancer.  
Therefore, our next aim was to examine the functional consequences of DATE truncation on HGF 
promoter activity in human CRC. We subcloned 1.1 kb hHGF promoter fragments harboring 
DATE with different numbers of adenosines (As) deleted, upstream of a luciferase reporter 
plasmid, and transfected these vectors into human CRC cell lines. Shortening of DATE (20A, 
25A) resulted in a significant increase in HGF promoter activity as compared to wild-type DATE 
(30A), suggesting that truncation (loss of deoxyadenosines) relieves the repressor function of 
DATE on the HGF promoter (Figure 15A). We carried out the same experiment in normal 
fibroblasts to confirm that truncation of DATE results in loss of its repressor function in normal 
cells (Figure 15B). Additional fine mapping studies showed that shortening DATE by even by 
one base (i.e. DATE with 29A) significantly increases promoter activity in HCT116, RKO and 
LOVO cell lines when compared to the activity of wild-type construct (Figure 15C and Table 
5). However, given that in human tissues, detecting the deletion of a single nucleotide through 
genotyping is difficult, we designated the loss of at least 2As as the threshold for DATE truncation 
in order to eliminate false positives. In order to test if DATE can influence promoter activity out 
of the context of HGF promoter, we engineered heterologous promoter constructs having DATE 
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with 14A or 30A placed upstream of the SV40 basal promoter driving the luciferase reporter gene. 
We noted that the heterologous construct consisting of truncated DATE was not capable of 
significantly suppressing SV40 driven luciferase reporter activity in comparison to the wild-type 
construct, further indicating that truncation results in the loss of its natural repressive function 
(Figure 15D). 
 
Figure 15.  DATE truncation causes reactivation of the silenced HGF promoter 
(A) Assessment of HGF Promoter activity in human CRC cell lines and (B) normal fibroblast cell 
lines transiently transfected with luciferase reporter constructs driven by human HGF promoter 
region (1.1 kb) harboring wild-type (30A) or shortened DATE. (C) Additional fine mapping 
studies (using luciferase reporter assay) carried out to determine the threshold of DATE 
shortening necessary to activate HGF promoter activity (D) Shortened and wild-type DATE were 
incorporated into a heterologous SV40 driven promoter to assess whether DATE can affect 
promoter activity out of the context of the HGF promoter. Bars are mean + SD for two 
experiments. Significant differences between the groups corresponding to p < 0.05, 0.01, 0.001, 
and no difference are depicted by *, **,  ***, and NS, respectively. 
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Table 5: Luciferase reporter assays are used to demonstrate that DATE truncation causes 
HGF promoter activation in CRC cells 
DATE constructs of varying lengths were used to drive the luciferase reporter. The + sign denotes 
significant increases in promoter activity in comparison to the 30A, wild-type construct. While 
the loss of even one deoxyadenosine resulted in significantly increased promoter activity in some 
CRC cell lines, given that detecting the deletion of a single nucleotide is difficult in human tissues, 
we designated the loss of at least 2A as the threshold for DATE truncation. 
3.4.2 DATE truncation leads to autocrine HGF-Met signaling in human CRC cells  
To determine whether DATE truncation affects the endogenous HGF expression in CRC 
cells, we analyzed human CRC cell lines that have wild-type or truncated DATE, for HGF and 
MET mRNA and protein expression.  We discovered that cell lines harboring wild-type DATE 
(HT-29 and SW620) do not express HGF mRNA or protein, while those cell lines with truncated 
DATE (HCT116, HCT-15, RKO, SW-48, LOVO) express robust levels of HGF mRNA and 
protein. All CRC cell lines, regardless of DATE status, expressed abundant MET mRNA and 
protein (Figure 16A-C).  Next, standard doses of pure recombinant HGF protein was run on a 
western blot and signal strengths (% intensity of staining) were measured using the Image J 
software program (Figure 16D). The signal strengths of these standardized controls were then 
compared to the densitometric signals of HGF protein from cell lysates, in order to approximate 
the HGF protein amount expressed by the CRC cell lines. Using this method, CRC cell lines 
harboring truncated DATE were estimated to express approximately 50-70 ng of HGF protein 
Cell line 20A 25A 26A 27A 28A 29A 30A
HCT116 + + - - - - -
SW620 + + - - - - -
RKO + + + + + - -
LOVO + + + + + + -
HCT-15 + + + + + + -
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(Figure 16E). Immmunoblotting for Met phosphorylation showed that Met was in an activated 
state in CRC cells having mutant DATE and expressing HGF, indicating that an autocrine HGF-
Met signaling loop is operational in these cells (Figure 16C and F).   
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Figure 16. DATE truncation leads to HGF production and autocrine HGF-Met signaling in 
human CRC cells 
(A, B) RT-PCR results indicating the presence of HGF transcript in DATE mutant CRC cell lines. 
(B) Detection of HGF and Met protein expression in human CRC cell lines using 
immunofluorescence. (C) Detection of HGF, Met, and phosphorylated Met (Tyr 1234/1235) 
expression in the human CRC cell lines using western blotting. (D) Top panel: A dose response 
of pure recombinant human HGF protein in western blot. Both pro-HGF and mature alpha chain 
of HGF are shown. Bottom panel: Quantification of HGF protein signal described above. Bar 
graphs indicate HGF protein expression measured as percent intensity using Image J software. 
(E) Quantification of HGF protein expression (ng/ 100 μg of total protein) in the human CRC cell 
lines using the standardized controls from (D). (F) Western blotting analysis of phosphorylated-
Met in human CRC cell lines quantified using densitometry and normalized to Met. Bars are 
mean + SD.   
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Next we asked whether DATE truncation by itself was sufficient to cause activation of 
the endogenous HGF gene. To assess this, we replaced the endogenous wild-type DATE in HT-
29 CRC cells with a truncated version (DATE with 12A, which is the shortest DATE we have 
noted to exist in tumor cells) using a somatic gene targeting approach employing the recombinant 
adeno-associated viruses (rAAV) vector for gene replacement. The gene targeting protocol is 
summarized in Figure 17A and C: top panel. We verified that the targeting event replaced the 
endogenous DATE with the truncated form by sequencing the DATE region (Figure 17B). HT-
29 clones, harboring the truncated DATE variant showed activation of the HGF gene, as indicated 
by expression of HGF transcript (Figure 17C, bottom panel). Notably, we observed that in some 
of these clones, truncated DATE reverted back to the wild-type DATE and HGF expression 
ceased over-time as cells were passaged (see clone #4 in Figure 17C bottom panel that is 
indicated by an asterisk). This is reasonable since HT-29 cells are MMR proficient and hence 
repaired the truncated DATE to its wild-type form. Together these results indicated DATE 
truncation is sufficient to activate HGF gene in human CRC cells.   
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Figure 17. DATE truncation is sufficient to activate endogenous HGF gene expression  
(A) Schematic representation of DATE replacement by homologous gene targeting approach 
showing the targeting vector and primers used to verify the targeting event. E1 and E2 exons 1 
and 2, respectively. (B) DNA sequencing data confirming that wild-type-DATE was replaced 
with truncated DATE following somatic gene targeting of DATE wild-type HT-29 cells. Note 
that the incorporation of 12A is underlined in the sequence. (C) Top panel: Replacement of 
endogenous DATE with the mutant version (12A). Bottom panel: HGF transcript is observed in 
the targeted clones that incorporated the mutant DATE construct. RNA from the DATE mutant 
cervical carcinoma cell line, C33A (indicated by arrow), was analyzed as a positive control. 
 
Our data so far indicated that DATE truncation is sufficient to activate the HGF promoter 
and leads to autocrine HGF-Met signaling in CRC cell lines. We next wanted to verify that this 
phenomenon was clinically relevant in human CRC patients.  Therefore, we assessed the status 
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of HGF and Met protein expression in DATE wild-type and DATE mutant human CRC tissues 
and corresponding adjacent normal tissues. Using IHC for HGF, we found that tumors with 
mutant DATE have robust HGF expression, whereas those with wild-type DATE showed nearly 
undetectable levels of HGF (Figure 18A). Adjacent normal epithelium (harboring wild-type 
DATE) of both DATE mutant and DATE wild-type tumors showed low/undetectable HGF 
expression (Figure 18A). The percent area and the intensity of HGF staining in the tumor tissues 
(as detected by IHC) were quantified using Image J analysis software. DATE mutant tissues were 
observed to have significantly increased HGF protein abundance in comparison to the tumors 
harboring wild-type DATE (Figure 18B). These findings were also confirmed by western blotting 
(Figure 18C) and densitometric analysis (Figure 18D). Additionally, we verified that human 
CRC tissues harboring mutant DATE and high HGF expression, are deficient in MMR proteins 
using IHC for MLH1 and MHS2 (Figure 18E).  
We previously noted that DATE is polymorphic in nature, and that normal human tissues 
can harbor truncated DATE variants (Figure 12B). We questioned whether normal adjacent 
colorectal tissues harboring mutant DATE exhibit increased HGF expression in comparison to 
those with wild-type DATE. We assessed the normal adjacent tissues of CRC patients using 
western blotting, and found that individuals with truncated DATE variant in their normal tissues 
showed significantly increased HGF expression, (particularly an increase in activated HGF β 
chain) in comparison to those harboring wild-type DATE (Figure 18F and G). These data 
suggested that similar to the HGF up-regulation in colorectal tumor tissues mediated by DATE 
mutagenesis, possessing the truncated DATE polymorphism could lead to increased overall HGF 
expression in normal human tissues as well.  
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Figure 18. DATE truncation correlates with HGF up-regulation in human CRC tissues 
Representative IHC for HGF, MET and the MMR proteins, MLH1 and MSH2, in DATE wild-
type and DATE mutant human CRC and their corresponding adjacent normal tissues. The arrow 
and the arrowhead shows increased HGF protein abundance and deficient MMR protein 
expression in DATE mutant tumors. (B) Quantification of HGF protein abundance from (A). (C, 
D) Western blot and densitometric quantification of HGF protein abundance in CRC tissues. (E) 
Representative IHC of HGF and MET protein abundance in MMR proficient and MMR deficient 
human colorectal tumor using tissue microarray platform. (F,G) HGF expression in normal 
adjacent tissues with truncated and wild-type DATE, assessed by western blot, and quantified 
using densitometry. Bars are mean + SE. Significant differences between the groups 
corresponding to p < 0.05 and p < 0.001 are depicted by * and *** respectively. 
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3.4.3 CRC cells with truncated DATE have operational HGF-Met signaling and are 
addicted to HGF for cell viability 
Our next goal was to investigate the functional consequences of aberrant HGF expression 
in CRC cells. We hypothesized that HGF producing CRC cells have an “oncogenic addiction” to 
HGF, and therefore rely on this growth-signaling axis for proliferation and survival. To test this 
possibility, we took a two-pronged approach that involved both blocking and activating the HGF-
Met signaling pathway, and assessing the outcome at the cellular and molecular levels. To block 
HGF-Met signaling, we treated human CRC cell lines that had DATE mutation and produce HGF, 
with a HGF neutralizing antibody or an IgG control antibody for 24 hours. We observed that 
activation of Met and its downstream signaling mediators, Akt and Erk, were dampened in 
response to HGF neutralization in cells harboring DATE mutations, resulting in reduced cell 
growth and viability, as detected by MTT cell viability assays (Figure 19A–C). In 
complementary studies, we tested whether the HGF-Met signaling in CRC cell lines mentioned 
above was indeed operational by stimulating serum-deprived cells with recombinant human HGF 
for 24 hours. We found that HGF treatment activated Met and its key downstream signaling 
effectors Akt and Erk (Figure 19D), and led to increased cell growth particularly in DATE mutant 
CRC cells (Figure. 19E and F). 
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Figure 19. DATE mutant CRC cells are addicted to HGF for cell growth  
(A-C) Neutralizing of HGF using HGF antibody for 24 hours blocks HGF signaling and inhibits 
cell growth. (A) Western blotting showing that HGF neutralization inhibits Met activation and 
signaling. (B) Representative phase contrast microscopy images of CRC cells treated with HGF 
antibody (C) The impact of HGF antibody on cell growth and viability. (D-F) Human CRC cell 
lines with mutant DATE have an operational HGF-Met signaling pathway as determined by gain 
of function studies using exogenous HGF. (D) Human CRC cells incubated with recombinant 
human HGF for 24 hours and assessed for Met activation and signaling by western blot. (E) 
Representative phase contrast microscopy images of CRC cells treated with exogenous 
recombinant human HGF. (F) The impact of HGF treatment on cell growth and viability. Bars 
are mean + SE.  Significant differences between the groups corresponding to p < 0.05, 0.01, 0.001 
are depicted by *, **, ***, respectively.  
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The results of the above described studies involving treatment of CRC cells with 
recombinant HGF or HGF neutralizing antibodies suggest that DATE mutant cell lines have a 
functional HGF-Met signaling system, and depend on this signaling axis for growth. To test this 
further, we inhibited the Met receptor with the highly specific, small molecule inhibitor of Met 
kinase called SU11274 121 and determined its effects on Met activation and cell growth behavior. 
Treatment with increasing concentrations SU11274 resulted in complete inhibition of Met 
activation and marked reduction of activation of its downstream signaling effectors Akt and Erk 
in DATE mutant HGF producing cells like HCT116 and RKO, and HCT-15 cell lines (Figure 
20A and B). SU11274 treated cells exhibited phenotypic characteristics of cell death such as 
detached, rounded and wrinkled cells (Figure 20C) and had significantly lower cell growth and 
viability (Figure 20D). Assessment of markers of apoptosis such as Caspase-3 (Figure 20E) and 
PARP cleavage (Figure 20A) showed only marginal or no alteration of these factors suggesting 
that inhibition of Met may cause cell death by an alternate pathway.  
The standard chemotherapy administered in human CRC is 5-FU, and cells exhibiting 
MSI-H phenotype are believed to be largely resistant to this treatment modality 82. Given that our 
data up to this point indicates that HGF-Met pathway plays a crucial role in human CRC cell 
survival, we asked whether inhibiting the HGF-Met signaling pathway could enhance human 
CRC cell killing by 5-FU treatment. Our results showed that while at low doses, single SU11274 
or 5-FU therapy had minimal effects on cell viability, combination therapy significantly enhanced 
cell death in the DATE mutant cell lines: MTT assays indicated significant loss of cell viability 
(Figure 20F) and phase contrast microscopy images showed notable phenotypic characteristics 
of cell death (Figure 20G) in the DATE mutant cell lines following 5-FU and SU11274 
combination treatment. Furthermore, dose response studies showed that, the concentration of 5-
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FU required to inhibit 50% of CRC viability (IC-50) was strikingly reduced when CRC cells were 
co-treated with SU11274, suggesting that Met inhibition may help increase the efficacy of 5-FU 
treatment in human CRC, particularly in MMR deficient patient subsets (Table 6).  
 
 
Table 6: IC-50 of 5-Fluorouracil in CRC cells, alone and in combination with the Met 
inhibitor, SU11274 (20 μM) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCT116 142.04 106.55
LOVO 223.13 85.54
HCT-15 554.26 357.32
RKO 121.05 85.54
CRC cell line IC-50 for 5-FU single treatment (μM)
IC-50 for 5-FU in combination with 
SU11274  (μM)
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Figure 20. Inhibition of HGF-Met signaling causes significant reduction in CRC cell 
viability 
(A) Representative western blot of CRC cells treated with various doses of Met inhibitor, 
SU12274, and assessed for indicators of Met activation and signaling. (B) Quantification of Met 
inhibition by increasing doses of SU11274. (C) Phase contrast microscopy of SU11274 treated 
CRC cells (D) Cell viability of CRC cells following 24 hours of SU11274 treatment. (E) Caspase 
activity used to assess apoptosis following Met inhibition.  (F) Cell viability assays of CRC 
treated with 5-FU alone and in combination with SU11274 for 24 hours. (G) Phase contrast 
microscopy of CRC cells treated with 5-FU alone and in combination with SU11274. Bars are 
mean + SE.  Significant differences between the groups corresponding to p < 0.01 is depicted by 
**. 
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3.4.4 Inhibition of autocrine HGF-Met signaling promotes induction of necroptosis in 
CRC  
Necroptosis is now understood to be an actively regulated, alternative pathway of cell 
death induced by a variety of stimuli. The release of HMBG1 into the media is a well documented 
biochemical indicator of necroptosis 122. Thus we analyzed SU11274 treated cells for this marker 
and discovered that Met inhibition indeed resulted in a dose-dependent increase in the HMGB1 
release in response to SU11274 (Figure 21A).  On the other hand, treatment with hydrogen 
peroxide, a well-known inducer of cell death through necroptosis, resulted in HMGB1 release 
that was totally abrogated when co-treated with exogenous HGF (Figure 21A). These data 
suggested to us that HGF-Met signaling axis has an anti-necrotic function. This notion was further 
supported by experiments in which we inhibited HGF-Met signaling by SU11274 and in the 
presence or absence of RIPK-1 inhibitor Necrostatin (Nec-1, a specific, allosteric inhibitor of 
RIPK-1 known to prevent necroptosis) 123.  The data showed that Nec-1 treatment significantly 
rescued cell death induced by Met inhibition (Figure 21B).  These results led us to postulate that 
HGF-Met axis may modulate the induction of necroptosis thorough RIPK-1.  Moreover, DATE 
wild-type, HGF non-expressing cells like HT-29, were found to be highly sensitive to TNF-
induced necrosis, whereas DATE mutant, HGF producing cells like HCT116, were resistant to 
TNFα but could be sensitized to it by blocking HGF-Met signaling with SU11274, further 
suggesting that HGF plays an anti-necrotic role (Figure 21C).   
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Figure 21. Inhibition of Met causes necroptosis in CRC cells   
(A) Human CRC cells were treated with the Met inhibitor for 24 hours, and assessed for the 
release of the necroptosis indicator, HMGB1, into the serum. Impact of HGF treatment on H202 
mediated release of HMGB1 was also assessed by western blot. (B) Necrostatin, an inhibitor of 
RIPK-1 was used to rescue the growth inhibition induced by treatment with the Met inhibitor in 
human CRC cells. (C) Human CRC cells were treated with SU11274 and TNFα to determine 
whether DATE mutant cells can be sensitized to TNFα induced necroptosis following inhibition 
of Met. Bars are mean + SE.  Significant differences between the groups corresponding to  
p < 0.05, p < 0.01, and p < 0.001 are depicted by *, **.***, respectively. 
 
Given that RIPK-1 is the key player of cell death induction by necroptosis 97,99,124 we 
asked whether HGF-Met has an impact on RIPK-1. We discovered that inhibition of Met by 
SU11274 induced a marked up regulation of RIPK-1 in a dose and time dependent manner 
(Figure 22A). On the other hand, activation of Met by exogenous HGF resulted in reduction of 
RIPK-1 in CRC cell lines and in primary cultures of rat hepatocytes (which are well known targets 
of HGF) (Figure 22B). The down regulation of RIPK-1 was highly specific to HGF treatment, 
and could not be observed when CRC cells were treated with the pan-kinase inhibitor, 
Staurosporine, or the agonistic anti-Fas antibody, CH11 (Figure 22C). We also investigated the 
ability of HGF to induce rapid RIPK-1 down-regulation in intact cells using immunofluorescence 
microscopy (Figure 22D). Under these conditions, TNFα was also able to achieve marginal 
RIPK-1 down modulation (Figure 22D), which was confirmed by western blot.  
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Figure 22. Active HGF-Met signaling down regulates RIPK-1 in CRC cells and primary rat 
hepatocytes 
(A) CRC cells treated with Met inhibitor for 6 hours caused up-regulation of RIPK-1, a key 
mediator of necroptosis. (B) Conversely HGF treatment down regulates RIPK-1. (C) Following 
treated of CRC cells with a variety of compounds for 6 hours, down regulation of RIPK-was noted 
to be specific to HGF. (D) Hep-G2 cells were treated with HGF or TNF for 30 minutes and 
processed for IF. HGF mediated down regulation of RIPK-1 was observed in intact cells, using 
immunofluorescence microscopy.  
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Encouraged by these data, we administered recombinant HGF at concentrations known to 
activate Met systemically to mice as we previously described 125, and analyzed the livers for 
modulation of RIPK-1. We observed a significant down regulation in RIPK-1 (within two hours) 
in HGF-treated mice as compared to the saline treated control mice, confirming our in-vitro data 
that HGF is capable of modulating RIPK-1 protein levels (Figure 23).  
 
 
 
 
 
 
Figure 23. HGF injection causes down regulation of RIPK-1 in vivo 
A total of 6 mice (db/db) were injected systemically with saline (N=3) or HGF (N=3, 0.5 ug/gr 
body weight) and their livers were harvested two hours later and analyzed for RIPK-1 expression 
by western blot. N.S. is a non-specific band, with Mw of 80 kDa depicted for equal loading. 
RIPK-1 down regulation was observed in the HGF treated cohort. 
 
We next examined human CRC tissues for RIPK-1 and HGF expression and found that those 
tumors with truncated DATE and upregulated HGF expression also have a significantly reduced 
levels of RIPK-1 protein as compared with DATE wild-type CRC tissues with low HGF 
expression. Tissues with high HGF and low RIPK-1 also exhibited fewer necrotic regions (areas 
where cells are lacking membranes and harbor heavy immune infiltration) (Figure 24A-C). 
Linear regression analysis revealed a strong negative correlation between HGF and RIPK-1 
protein levels: high HGF protein abundance significantly associated with lower levels of RIPK-1 
protein (Figure 24D, p < 0.01).  
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Figure 24. HGF expression correlates with down regulation of RIPK-1 in human CRC 
patient tissues  
(A) DATE mutant and wild-type human CRC tissues were stained for HGF and RIPK-1. DATE 
mutant CRC tissues showed high HGF expression, as depicted by the representative 
immunohistostaining images. (B) Tumors with high HGF had low RIPK-1, and exhibited fewer 
signs of necrosis. Necrotic regions (indicated by arrowheads, depict regions with cells lacking 
cell membranes and having heave immune infiltration) are present in HGF negative tumors (C) 
HGF and RIPK-1 protein abundance in the immunohistochemically stained CRC tissue sections 
were quantified using Image Analysis Software. (D) Linear regression analysis of the above-
described data indicated that HGF and RIPK-1 protein expression showed a significantly negative 
correlation. Bars are mean + SEM for n= 40. Significant differences between the groups 
corresponding to p < 0.001 is depicted by ***. 
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3.4.5 Autocrine HGF-Met signaling promotes escape from necroptosis via direct post 
translational modification and modulation of RIPK-1 
The above data prompted us to decipher the underlying mechanisms of HGF-Met 
mediated RIPK-1 down regulation and escape from necroptosis. It is reported that RIPK-1 is 
highly regulated post-translationally. Given that our intitial studies indicated that down- 
regulation is not at the mRNA level, we hypothesized RIPK-1 down-regulation may occur at the 
protein level. It is well-known that upon stimulation by cytokines like TNFα, RIPK-1 is recruited 
from the cytoplasm to the plasma membrane and polyubiquitinated (Lys63-linked chain). This 
RIPK-1 is incorporated into a signalosome that leads to NF-κB activation and is then degradaed 
via the proteosome to terminate signaling 97,99,102,124,126. To determine whether HGF-Met axis 
induces RIPK-1 recruitment to the plasma membrane, we treated CRC cells with HGF, 
fractionated cell lysates to plasma membrane (M) and cytosolic portions (C) and assessed RIPK-
1 levels. We found that greater than 90% of the RIPK-1 pool resides in the cytosolic fraction in 
unstimulated cells. HGF treatment induced marked recruitment of RIPK-1 to the plasma 
membrane within one hour of treatment. Quantification of the data showed that HGF treatment 
induced significant recruitment of RIPK-1 to plasma membrane which reached more than 60% 
and was accompanied by a proportional reduction of RIPK-1 abundance in the cytoplasm (Figure 
25A and B). Further exploration of the time course of RIPK-1 recruitment to the plasma 
membrane by HGF revealed that it occurs rapidly within 10 minutes of HGF stimulation which 
was concomitant with Met activation (Figure 25C). Met was mainly found in the plasma 
membrane fraction whereas cIAP1 was largely cytosolic (Figure 25C). In these experiments 
TNFα was used as a positive control as it is a well known inducer of RIPK-1 recruitment to the 
plasma membrane 102.  It is important to note that HGF-induced RIPK-1 recruitment to plasma 
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membrane could be enhanced when HGF treatment was done in the presence of proteasome 
inhibitor MG-132 (Figure 25C), suggesting that recruited RIPK-1 is rapidly degraded by the 
proteasome.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. HGF-Met signaling causes rapid recruitment of RIPK-1 to the plasma membrane 
(A) CRC cells were pre-treated with MG-132 for one hour and then stimulated with or without 
HGF as indicated and assessed for RIPK-1 by western blot. (B) Quantification of the data by 
densitometric analysis. (C) Time course of RIPK-1 recruitment to plasma membrane by HGF.  
CRC cells were pre-treated with or without MG-132 for one hour and then stimulated with or 
without HGF or TNFα as indicated. C denotes cytosolic fraction and M membrane. RIPK-1 level 
was assessed by western and the blots were then sequentially, re-probed for the indicated proteins. 
Bars are mean + SD. Significant differences between the groups corresponding to p < 0.001 is 
depicted by ***. 
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 The ability of HGF to impact RIPK-1 at the cellular level was investigated using 
immunofluorescence microscopy in intact cells . Figure 26 depicts that in unstimulated cells 
RIPK-1 105 shows a highly diffused cytoplasmic pattern of distribution whereas Met shows plasma 
membrane localization. Stimulation with HGF (but not TNF) provoked a pronounced 
redistribution of RIPK-1 to the plasma membrane within 20 minutes of treatment. Interestingly, 
both Met and RIPK-1 formed highly punctate patterns of staining (indicated by the arrowheads 
in Figure 26) which is a hallmark of Met clustering and internalization.  
 
 
 
 
 
 
 
 
 
 
 
Figure 26. HGF-Met signaling results in down regulation of RIPK-1 in vivo  
Hep-G2 cells were treated with or without HGF or TNFα and assessed for RIPK-1 using 
immunofluorescence microscopy. Rabbit and mouse IgG were used as negative controls for 
staining. The images indicate that HGF-Met axis impacts RIPK-1 cellular distribution using 
RIPK-1 and Met specific antibodies as indicated. Arrowheads indicate that HGF causes robust 
redistribution of RIPK-1 to the membrane. (note the punctate staining). 
 
Membrane associated RIPK-1 exhibited a ladder/smear pattern of migration in the 
presence of the proteasome inhibitor, MG132, which is a hallmark of polyubiquitinylation 
(Figure 27A). Polyubiquitinated RIPK-1 is proposed to induce some cell survival genes via 
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activating p65 subunit of NF-κB 97,99,103,124. Notably, we observed that down-regulation of RIPK-
1 by HGF did not affect the level of phosphorylated p65, an indicator of active NF-κB mediated 
cell survival signaling (Figure 27B).  To directly assess whether RIPK-1 is indeed ubiquitinated 
by HGF treatment, we immunoprecipitated RIPK-1 from CRC cell lysates and immunoblotted 
with total and linkage specific (Lys48 and Lys63) ubiquitin antibodies. Untreated or MG132 
treated cells did not exhibit RIPK-1 ubiquitination. However, cells treated with the combination 
of HGF and MG132 showed robust RIPK-1 ubiquitination which was mainly of the Lys48-linked 
chain type, indicating that it is destined for degradation by the proteasome machinary. Of note, 
we found that Met and RIPK-1 form a complex following HGF stimulation, since Met was 
immunoprecipitated with RIPK-1. Interestingly, this was observed only in samples treated with 
HGF and MG132 (Figure 27C) suggesting that Met-RIPK-1 complex is very unstable.  
Figure 27. HGF induces polyubiquitination of RIPK-1  
(A) Serum deprived CRC cells were treated with or without HGF in the presence or absence of 
MG-132 for three hours. Membrane fraction was prepared and assessed for RIPK-1 by western 
blot. (B) HepG2 cells were treated with or without HGF or TNFα for 30 minutes and assessed by 
western blotting. Down regulation of RIPK-1 by HGF was found to not affect phospho-p65 levels.  
(C) CRC cells were treated with or without HGF in the presence of absence of MG-132 and their 
lysates were subjected to IP with RIPK-1 antibody, and western blotting was performed as 
indicated to detect ubiquitination of RIPK-1 and its association with Met. 
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It is known that RIPK-1 is polyubiquitinated by E3 ligases like TRAF-2. We therefore 
hypothesized that RIPK-1 polyubiquitinylation induced by HGF may be carried out by TRAF-2. 
We uncovered that like RIPK-1, TRAF-2 was indeed recruited to the plasma membrane with HGF 
treatment in Hep-G2 cells (Figure 28A).  Blotting for Met was used to distinguish the membrane 
fraction and C-IAP was used to identify the cytoplasmic fration, as well as to confirm equal 
protein loading. We also noted that HGF treatment induced a western blot banding pattern that 
resembled ubiquitination of  TRAF-2 (Figure 28B). Immunoprecipitation of TRAF-2 from the 
membrane lysates and western blotting for RIPK-1 indicated that HGF also induced association 
of TRAF-2 to RIPK-1 and that TRAF-2 polyubiquitination (likely self-induced) was primarily of 
the Lys48-linked type (Figure 28C).  
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Figure 28. HGF stimulation causes the recruitment of TRAF-2 to plasma membrane and  
its association with RIPK-1 
(A) Serum deprived HepG-2 cells were pre-treated MG-132 for one hour and then with HGF or 
TNFα for 30 minutes and the lysates were subjected to western blot to detect TRAF-2 cellular 
localization. (B) Serum deprived HepG-2 cells were treated with or without HGF for 30 minutes 
and their cytosolic (C) and membrane (M) fractions were subjected to western blotting for TRAF-
2. It was noted that HGF induces polyubiquitination of plasma membrane associated TRAF-2. 
(C) Lysates from (A) were IP with TRAF-2 antibody and western blotted for RIPK-1 to detect 
association. Polyubiquitin antibodies were used to detect ubiquitination of TRAF-2. 
 
Given the fact that Met is a tyrosine kinase and RIPK-1 could be recruited to the plasma  
membrane by Met activation and the finding that Met and RIPK-1 associated with each other, we 
asked if Met can tyrosine phosphorylate RIPK-1 hence targeting it for ubiquitination. Phospho-
tyrosine sites in target proteins are well-known to act as binding sites for E3 ligases leading to 
ubiquitinylation of the target proteins. Indeed, Met itself once activated by HGF, 
autophosphorylates on tyrosine residue 1003 which then recruits E3 ligase Cbl leading to 
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ubiquitinylation and degradation of Met and its associated proteins via proteasome 127. Thus we 
performed immunoprecipitation and western blot studies using RIPK-1 and phosphotyrosine 
antibodies to test if RIPK-1 becomes tyrosine phosphorylated by Met. Remarkably, we 
discovered that HGF induced tyrosine phosphorylation of RIPK-1 (Figure 29A). Time course 
experiments revealed that HGF stimulation causes rapid and transient tyrosine phosphorylation 
of RIPK-1 within 30 minutes  (immunoprecipitation with phosphotyrosine antibody pY20 and 
immunoblotting with RIPK-1 Figure 29B. Collectively, these data suggested that RIPK-1 is most 
likely directly tyrosine phosphorylated by Met. To test this further, we incubated pure 
recombinant active human Met kinase (His-tgged, 55 kDa) with pure recombinant active RIPK-
1 (GST-tagged full-length RIPK-1, 110 kDa) in kinase buffer and assessed for RIPK-1 tyrosine 
phosphorylation. Incubation of Met with RIPK-1 resulted in robust tyrosine phosphorylation of 
RIPK-1 (Figure 29C). Proteomic analyses using MS/MS MALDI-TOF identified that RIPK-1 
became phosphorylated by Met at Tyr384 residue. The sequence of this site is KLQDEANYHL 
and is located in the intermediate domain of RIPK-1 near K377, which is the major site of RIPK-
1 ubiquitination 97,100,124. We found that this Tyr site and the motif (KLQDEANYHL) are highly 
conserved in various organisms from humans down to at least Xenopus indicating its functional 
importance. We subsequently asked whether tyrosine phosphorylation of RIPK-1 has functional 
consequences. It is known that RIPK-1 activates itself through the autophosphorylation of the 
serine residues within its kinase domain 99. Notably, we found that tyrosine phosphorylation of 
RIPK-1 by Met resulted in marked reduction of RIPK-1 activity, as indicatated by the signifciant 
reduction in serine phosphorylation of RIPK-1 (Figure 29C and D).  
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Figure 29. Met directly tyrosine phosphorylates RIPK-1 decreasing its autocatalytic activity 
as indicated by the reduction in RIPK-1 serine phosphorylation  
(A) CRC cells were treated with or without HGF in the presence or absence of MG-132, and their 
membrane fractions were subjected to IP with RIPK-1 antibody and western blotting with 
phosphotyrosine and phosphoserine antibodies.  (B) Serum deprived CRC cells were treated with 
or without HGF and the lysates were subjected to IP with a phosphotyrosine antibody (pY20) and 
then western blotted for RIPK-1. (C) An in-vitro kinase assay was performed by incubating pure 
recombinant human Met Kinase with varying amounts of pure recombinant human RIPK-1 in 
kinase buffer for 30 minutes. The samples then subjected to western blotting, to detect tyrosine 
and serine phosphorylation of RIPK-1. (D) Quantification of RIPK-1 serine autophosphorylation 
from (C) indicating loss of RIPK-1 kinase activity following incubation with Met kinase. Bars 
are mean + SD. Significant differences between the groups corresponding to p < 0.001 is depicted 
by ***. 
 
In order to determine whether the ability to phosphorylate RIPK-1 is limited to Met, we 
performed an in-vitro kinase assay using recombinant human RIPK-1 and several different human 
pure recombinant tyrosine kinases (EGFR, INSR,SRC). We found that all of the tested tyrosine 
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kinases were capable of phosphorylating RIPK-1 as indicated by western blotting of the kinase 
assay samples with the pY-20 phosphotyrosine antibody (Figure 30). We noted that incubation 
of RIPK-1 with INSR showed particularily robust tyrosine phosphorylation of RIPK-1, while 
weaker phosphoryation was observed following incubation with SRC.  Additionally, although 
EGFR appears to phosphorylate RIPK-1 (as indicated by the stronger western blot stain observed 
when RIPK-1 was incubated with EGFR), due to the fact that EGFR runs at a molecular weight 
similar to that of RIPK-1, no concrete conclusions regarding its impact on RIPK-1 could be made. 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. RIPK-1 can be phosphorylated by multiple tyrosine kinases 
An in-vitro kinase assay was performed by incubating multiple human pure recombinant tyrosine 
kinases (Met, EGFR, INSR, and SRC) with pure recombinant human RIPK-1 in kinase assay 
buffer for 30 minutes. The samples were then subjected to western blotting using phosphotyrosine 
antibodies to detect phosphorylation of RIPK-1. 
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3.4.6 Autocrine HGF-Met signaling associates with negative patient prognosis in CRC 
We next asked whether DATE mutagenesis in CRC impacted patient prognosis. We found 
that DATE mutant tumors were significantly larger as compared to DATE wild-type tumors 
(average tumor size of 7.27 cm vs. 4. 96 cm (p < 0.01). High HGF protein abundance in tumors 
(as observed in DATE mutant tumors) also significantly associated with advanced tumor stages 
(Figure 31A, p < 0.001). Kaplan-Mier survival analysis indicated that patients with mutant 
DATE and low RIPK-1 protein abundance exhibited significantly lower 5- year survival in 
comparison to those with wild-type DATE and high levels of RIPK-1 protein (P= 0.0003, and 
0.001, respectively, (Figure 31B and C). 
Figure 31. DATE mutation and low RIPK-1 levels associate with poor patient prognosis 
(A) Quantification of RIPK-1 and HGF protein abundance were assessed by IHC and quantified 
using Image Analysis Software. Tumors were classified as low (TMN stage I and II) or high 
(TMN stage IV) stage using the pathology reports of the samples. Tumors with high HGF 
expression displayed advanced tumor stages overall, while those with low HGF expression 
exhibited low tumor stages. Bars are mean + SEM for n= 40. (B, C) Kaplan-Mier survival analysis 
was performed to determine the association of (B) DATE mutation and (C) RIPK-1 levels with 
5-year CRC patient survival. Significant differences between the groups corresponding to p < 
0.001 is depicted by ***. 
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3.5 DISCUSSION 
CRC is the third leading form of cancer related death worldwide, and despite the 
therapeutic advances pioneered over the last decade that have led to significant increases in patient 
survival, nearly 50% of patients who undergo surgery, die of metastatic disease. Given its bleak 
prognosis, novel therapeutic targets and innovative strategies are needed to improve the future 
outlook of CRC 128. Our findings indicate that HGF-Met signaling pathway is aberrantly activated 
in a significant subset of human sporadic CRC, and that HGF-Met signaling axis presents a 
potential therapeutic target for the personalized treatment of CRC. 
 Deregulated growth factor signaling is a cardinal features of cancer cells 73. For instance, 
gene overexpression of HGF/Met, and ligand independent activation of Met, among other 
mechanisms, are believed to play crucial roles in non-small cell lung carcinoma (NSCLC), gastric, 
ovarian, pancreatic, thyroid, breast, head and neck, colon and kidney cancers 48. While the role of 
aberrant HGF-Met signaling in promoting un-regulated cell survival and growth is well 
documented, the detailed molecular mechanisms involved are yet to be fully understood. Our 
work here elucidates the causes and the consequences of aberrant HGF production and autocrine 
HGF-Met signaling in CRC.  
It is well known that both chromosomal and microsatellite instability promote colorectal 
tumorigenesis by leading to the accumulation of mutations in tumor suppressors and oncogenic 
driver genes 73,129. Our initial investigations (Data shown in Section 2) revealed that defective 
MMR mediated MSI is the underlying cause of a HGF gene promoter mutation (interchangeably 
referred to as DATE truncation). Furthermore, DATE mutagenesis significantly associated with 
the incidence of CRC, suggesting that it plays roles in the onset and/or maintenance of the 
malignant phenotype. Our studies regarding the consequences of DATE mutation in cancer (Data 
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shown in Section 3) indicated that shortening of DATE is sufficient to promote transcriptional 
activation of the otherwise silenced HGF gene in colonic epithelial cells. In other words, 
truncation of DATE relieves its repressive function, leading to dysregulated, autonomous HGF 
production in epithelial cells, which are normally subject to paracrine signaling via HGF that is 
produced by the stromal cells. We noted that autocrine production of HGF causes activation of 
the oncogenic driver kinase, Met, and confers a selective growth advantage by stimulating cell 
proliferation, survival, and escape from necroptotic cell death. These findings are further 
discussed below.   
HGF-Met signaling is known to promote cell growth by inhibiting apoptosis and by 
inducing cell proliferation via activation of PI3K/Akt/mTOR/p70S6K and MAPK/ERK 49. 
Concurring with these reports, the treatment of DATE mutant CRC cell lines with HGF 
neutralizing antibody or a small molecule Met kinase inhibitor, resulted in significantly reduced 
activation of Met and its key downstream effectors, leading to reduced cell growth and viability, 
while stimulation with HGF led to the converse results. These findings suggested that DATE 
mutant CRC cells exhibit an “oncogenic addiction” to HGF-Met signaling.  
Programmed necrosis, dubbed necroptosis, is initiated by death receptor signaling (such 
as tumor necrosis factor receptor 1 and FAS) and requires the kinase activity of RIPK-1, which 
autophosphorylates itself and subsequently RIP-3, leading to the formation of the necrosome 97. 
Our understanding of the role of growth factor signaling in preventing necroptosis is lacking, and 
the mechanisms involved are yet to be discerned. Our report here shows for the first time that 
RIPK-1 is directly regulated by HGF-Met, and will serve as a pioneering milestone in further 
exploration of this area. We discovered that in human CRC, HGF-Met protects against 
necroptosis by down regulating RIPK-1. Interestingly, we also discovered that RIPK-1 down 
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regulation in response to HGF also occurs in primary hepatocyte cultures and in the livers mice 
injected with HGF, indicating that modulation of necroptosis by HGF-Met signaling is not limited 
to CRC and cell culture. We showed here that following HGF stimulation, RIPK-1 is recruited to 
the membrane where it then becomes tyrosine phosphorylated on residue 384 and subsequently 
polyubiquitinated likely by TRAF-2. RIPK-1 is a known substrate of TRAF-2 130 and E3 ubiquitin 
ligases such as TRAF-2 are known to self-regulate through polyubiquitin modification 131. 
Interestingly, we found that following HGF stimulation TRAF-2 becomes polyubiquitinated 
(Lys48-linked) at the plasma membrane. According to the current models, RIPK-1 is believed to 
participate in inducing cells survival, inflammation, and death by forming different protein 
complexes 97,99,103,124. Complex I is believed to form rapidly at the plasma membrane upon 
stimulation with pro-inflammatory stimuli like TNFα and contains TNFR-1, TRADD, RIPK-1, 
TRAF-2, and cIAP1/2 102. In this complex, RIPK-1 becomes polyubiquitinated (Lys63-linked 
chain type), and acts as a docking site for recruitment and activation of the components of the 
NF-κB pathway. RIPK-1 then undergoes process of ubiquitin editing by A20 and Cyld and its 
polyubiquitin moiety switches to Lys48-linked chain kind, which targets it to proteasomal 
degradation to terminate NF-κB induction 97,99,103,124 
Under some stress conditions, this activated RIPK-1 undergoes dissociation and forms 
complex IIA, which contains active RIPK-1, FADD, and Caspase-8, which can induce apoptosis. 
Alternatively, complex IIB, which is composed of RIPK-1 and RIP-3, can form and provoke 
necroptosis (especially when apoptotic Caspases are inhibited) 102. Interestingly, we previously 
reported that Met also prohibits apoptosis by sequestering Fas 132,133 and also by directly inhibiting 
Caspase-3 by the virtue of harboring a novel decoy like capsase-3 site, which consists of 
DNADDEVDT motif, located at Met’s c-terminal end. This site has two tandem Caspase-3 
 120 
cleavage sites that entrap and inhibit the active site of Caspase-3 during the cleavage process 134. 
It should be noted that modulation of RIPK-1 by HGF treatment did not dampen phosphorylation 
of NF-κB p65 subunit, indicating NF-κB activation was not affected. Regardless, RIPK-1 was 
recently discovered to play a non-essential role in NF-κB signaling as determined by experiments 
using RIPK-1 deficient MEFs 130.  Moreover, we showed that tyrosine phosphorylation of RIPK-
1 by Met, inhibited the kinase activity of RIPK-1. Notably, detailed structure-function studies 
have shown that the kinase activity of RIPK-1 is not required for NF-κB activation (RIPK-1 
merely acts as scaffold and docking site to activate NF-κB), but is essential for induction of 
necrosis 97,99,124,130.   Based on these outcomes, we believe that HGF-Met axis down-regulates 
RIPK-1 and prevents the onset of necroptosis, without influencing pro-survival NF-κB signaling, 
thus, creating an ideal molecular environment for cancer cell survival and proliferation.  
Our findings also have important clinical implications since we found that HGF 
overexpression in the tumor correlated with reduced levels of RIPK-1, larger tumor size, high 
tumor stage and poor patient survival. We showed that HGF expressing tumor cells have 
operational HGF-Met autocrine circuit and that HGF down regulates RIPK-1. On the other hand, 
blocking Met signaling by small molecule Met inhibitor like SU11274, dramatically up regulated 
RIPK-1 and induced necroptosis. Our results suggest that necroptosis is a major mechanism of 
cancer cell death that may be inhibited via the activation of HGF-Met signaling. Our proposed 
model for HGF gene mutation and its molecular consequences are shown in Figure 32. 
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Figure 32. Model of the causes and consequences of HGF gene mutation in human CRC 
 
The clinical benefits of inducing necroptosis in cancer have been recently documented in 
multiple studies. For instance, radiation treatment was noted to induce RIPK-1 dependent 
necroptosis in anaplastic thyroid and adrenocortical cancer cells, and promote tumor reduction 
135. Our findings suggest that inhibition of HGF-Met signaling can induce RIPK-1 mediated 
necroptosis and thus presents a viable therapeutic strategy in the treatment of human CRC. There 
are a number of Met kinase inhibitors and anti-HGF therapies currently in phase I and II clinical 
trials for the treatment of lung, renal, gastric, brain and colorectal cancer 48,68. The targetable 
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nature of HGF-Met signaling in CRC was recently demonstrated using a selective small molecule 
Met kinase inhibitor, ARQ 197 (Tivantinib). In-vitro assays using ARQ 197 showed a dose and 
a time-dependent decrease in the proliferative capacity of CRC cell lines, and ARQ 197 injection 
in mice bearing CRC cell line xenografts caused inhibition of tumor growth 136. In phase I clinical 
trials, Tivantinib was well tolerated and showed encouraging anti-tumor activity in patients with 
metastatic CRC in-conjunction with the chemotherapeutics, Irinotecan and cetuximab 71. MMR 
deficiency and MSI is documented to play a fundamental role in a number of other malignant 
conditions beside hereditary non-polyposis colorectal cancer (HNPCC Lynch syndrome and its 
associated cancers), such as cancers of the endometrium, stomach, pancreas-biliary tract, small 
intestine, urothelium, ovary and glioblastomas 76,82,108,109.  Our work encourages further studies 
to develop modalities by which HGF-Met can be efficiently targeted in tumors for the treatment 
of CRC.  
We previously showed (In Section 2) that DATE is polymorphic in nature and that the 
truncated DATE variant occurs in the general population at an overall frequency of about 8%. 
Here, we uncovered that normal colonic tissues of subjects with truncated DATE variant have 
higher HGF expression than those with wild-type DATE. We speculate that having the truncated 
DATE (hence hyperactive HGF promoter variant) is a double-edged sword; it can provide robust 
HGF expression and promote efficient tissue regeneration and repair, but it also can promote 
tumorigenesis if sufficient genetic/epigenetic lesions in key oncogenes and tumor suppressor 
genes accumulate. We suspect that harboring truncated DATE polymorphism and high HGF 
production in normal tissues contribute to earlier malignant transformation and more aggressive 
tumor growth in patients. Our work uncovered that the incidence of truncated DATE in normal 
tissues is significantly higher within the African American population. Interestingly, a recent 
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study of dialysis patients found significant up-regulation of HGF in the serum of African-
American patients, in comparison to the Caucasian counterparts 137.  This observation, combined 
with our data, suggests that the increased incidence of polymorphic DATE and the resultant 
autocrine HGF production by normal cells may underlie the up-regulated serum HGF levels 
observed in African Africans. Although our sample size was relatively small, given the strong 
oncogenic properties of active HGF-Met signaling, these findings also imply that the elevated 
incidence of truncated DATE polymorphism in normal tissues may be partly responsible for the 
early tumor onset and the worsened prognosis observed within the African American CRC patient 
cohort. Future large-scale population studies are needed to determine whether individuals with 
truncated DATE variant are predisposed to CRC.  
Our work identified autocrine activation of HGF-Met signaling as a potential therapeutic 
target in human CRC. Our model for the manner in which autocrine HGF production in cells 
provides a selective growth advantage and likely contributes to colon carcinogenesis is shown in 
Figure 33. The findings of this study encourage further clinical investigations to establish routine 
DATE testing and anti-HGF/Met therapy for the treatment of CRC patients harboring DATE 
mutations. Our report also provides impetus for investigations of the dynamic modulation of 
RIPK-1, not only by HGF-Met, but also potentially by other tyrosine kinase growth factor 
receptors.  Finally, given the importance of RIPK-1 in promoting inflammation, and its ability to 
be modulated by HGF, we suggest additional studies to determine whether HGF can suppress 
inflammation both within and outside the context of cancer. 
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Figure 33. Proposed model outlining the role of autocrine HGF production in colon 
tumorigenesis 
Proposed model showing that mutator phenotype due to germline (i.e. HNPCC) and/or somatic 
mutation of MMR genes causes HGF gene promoter mutation and activation, leading to HGF 
autocrine production in colonic epithelial cells (shown in red). Autocrine HGF in turn confers a 
selective growth advantage, and in corporation with other deregulated essential players, (i.e. 
oncogenes and tumor suppressors genes), drives colon tumor promotion.  
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4.0  IMPLICATIONS AND FUTURE DIRECTIONS 
Mortality from CRC accounts for a significant portion of cancer related deaths worldwide. 
Current treatment methods include local endoscopic resection, extensive surgery (may include 
lymph node resection), as well as adjuvant and non-adjuvant chemotherapy.  While the treatment 
strategies and the degree of therapeutic success differ depending on the stage of diagnosis, the 
overall bleak prognosis of metastatic and recurring CRC highlight the tremendous need for novel 
therapeutic targets and approaches. Given the well-known tumorigenic role played by the HGF-
Met signaling pathway in a number of malignancies, we aimed to identify whether HGF 
undergoes mutagenesis and plays an oncogenic role in human CRC. 
Our work is the first to indicate that a subset of CRC patients harboring HGF promoter 
mutations may benefit from inhibition of the HGF-Met signaling axis. We were also the first to 
demonstrate that genomic instability provoked by faulty DNA mismatch repair leads to HGF gene 
promoter mutation and the oncogenic addiction of human CRC cells to autocrine HGF-Met 
signaling. We uncovered that the subset of CRC patients harboring HGF promoter mutations 
present considerably larger tumors and significantly reduced 5-year survival. These findings 
suggest that DATE status has prognostic significance in human CRC. The well tolerated Met 
inhibitor, Tivantinib, is currently being tested in phase II clinical trials for the treatment of human 
CRC 71.  While the Tivantinib study aims to assess the overall patient response to anti-Met 
therapy, our data suggests that maximal therapeutic benefit may be achieved in those harboring 
truncated DATE. Although additional studies are needed to confirm the clinical relevance of 
DATE, our findings imply that stratification of CRC cases by DATE status may be useful in 
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predicting who will benefit from targeted Met therapy, and aid in the development more effective 
and personalized treatment plans.  
Escape from controlled cell death is a hallmark of cancer cells 73. Studies of molecular 
mechanisms of human CRC have revealed that defective cell death signaling is fundamental to 
the onset and progression of CRC.  To date, resistance to apoptosis has been identified as the 
major cause of therapeutic failure and disease recurrence, and thus, nearly all non-invasive 
therapeutic approaches have aimed to promote CRC cell apoptosis 138. However, given the recent 
findings indicating that escape from alternate forms of controlled death (such as necroptosis) play 
crucial roles in maintaining the malignant phenotype, our current understanding of the landscape 
of cell death in cancer is rapidly changing. Our investigations described here, as well as a number 
of other recent studies, imply that evasion of necroptosis significantly contributes to colorectal 
carcinogenesis and therefore presents a novel therapeutic target 138. Our results are of particular 
significance, as they demonstrate for the first time that receptor growth factor signaling can inhibit 
necroptosis via direct post-translational modification and proteasome-mediated down regulation 
of a critical necroptosis executioner protein, RIPK-1. We also showed that down regulation RIPK-
1 via HGF-Met signaling associates with poor CRC patient prognosis, suggesting that escape 
from necroptosis makes significant contributions to tumor progression. Our findings encourage 
further investigations into the role of RIPK-1 in cancer and whether growth factor signaling and/or 
RIPK-1 present viable therapeutic targets in the treatment of colorectal and other human cancers.   
While it may be beneficial to induce necroptosis in cancer to achieve tumor reduction, 
disease situations exist where it is advantageous to prevent the onset of necroptosis. For instance, 
excessive necroptotic cell death in the intestinal epithelium is observed in chronic inflammatory 
diseases such as Crohn's disease and ulcerative colitis. Terminal ileum biopsies from patients 
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suffering from Crohn's disease show necroptotic cell death at the crypt base. It’s been speculated 
that Paneth cell abnormalities and the constitutive expression/activation of RIPK1 and RIP-3, 
contribute to the elevated necroptosis observed in the ileum and the pathogenesis of Crohn's 
disease 139. Our novel findings indicating that activation of HGF-Met signaling down-regulates 
RIPK-1 may be applicable in the management of Crohn's disease and ulcerative colitis. We 
propose further investigations to determine whether the treatment of Crohn's disease patients with 
HGF could inhibit excessive intestinal necroptosis and provide a viable therapeutic strategy to 
manage inflammatory bowel disease.   
The difficulty in developing safe and effective cancer therapies lies not in the inability to 
identify chemicals capable of eliminating cancer cells, but in ensuring that the drug concentrations 
at which cancer cells are eradicated cause minimal harm to the normal tissues of the patient. Most 
chemotherapeutic agents were historically identified based on their in vitro capabilities to 
eliminate rapidly dividing cells. As such, these agents generally kill rapidly dividing normal cells 
including the bone-marrow hematopoietic precursors and gastrointestinal mucosal epithelial cells, 
and cause irreversible injury to certain non-rapidly dividing normal tissues as well. Furthermore, 
using higher concentrations of chemotherapeutics can result in off-target effects that lead to 
increased toxicity and unforeseen biological effects. In order to improve these narrow therapeutic 
windows and eliminate cancer cells with minimal patient toxicity, combination therapy may be 
utilized 140. Synthetic lethality traditionally refers to a situation where a single mutation in either 
of two genes is compatible with survival, but simultaneous mutations in both genes induce cell 
death 141. This model can also be extended to define lethal interactions between two drugs, such 
as that observed with the use of targeted EGFR inhibitors and cytotoxic agents. For instance, 
combining traditional chemotherapeutics such as 5-FU and Cisplatin with molecularly targeted 
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therapies such as the EGFR inhibitor, Cetuximab, has resulted in significant prognostic 
improvements in metastatic colorectal and head and neck cancer patients. In this case, Cetuximab 
targets EGFR overexpression on the cancer cells, while 5-FU therapy inhibits DNA replication, 
leading to tumor cell death and improved therapeutic responses in patients receiving the 
combination therapy in comparison to those receiving single treatments 142. Similarly, our work 
indicated that inhibition of Met in combination with other treatment modalities, such as TNFα 
and 5-FU results in increased tumor cell death. TNFα has been approved for the treatment of 
melanoma and soft-tissue sarcomas in Europe, and 5-FU is used as the standard therapy in CRC.  
Despite their remarkable anticancer activities, both agents pose significant toxicity to the patient. 
Our data suggests that using low doses of TNFα/5-FU treatments in combination with HGF-Met 
inhibitors, may allow for tumor reduction with minimal patient toxicity.  
 While our work sheds new light on the causes and consequences of HGF gene mutation 
in CRC, it also strongly highlights the need for future experimentation to answer the many 
questions raised by our findings. All our studies on the cell killing abilities of HGF-Met inhibition 
were largely based on in-vitro data.  Therefore, we propose the use of mouse xenografts using 
human CRC cell lines to verify the anti-tumor activity of small molecule Met inhibitors and anti-
HGF neutralizing antibodies, in vivo, alone and in combination with other cytotoxic agents.  We 
also uncovered that DATE is polymorphic in nature and that presence of the truncated DATE 
variant in adjacent normal tissues associates with increased HGF production.  Given the well-
known tumorigenic properties of deregulated growth factor signaling, we postulate that harboring 
the truncated DATE variant in normal tissues may predispose individuals to develop CRC. To 
assess this, we propose the screening of normal individuals for DATE polymorphisms and 
performing 10-20 year prospective studies to evaluate the relationship between truncated DATE 
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and risk of CRC. Our findings also indicated that DATE mutagenesis in tumor associated with 
larger tumor size and worsened patient prognosis. Given these findings, we recommend extending 
the study of DATE to larger patient cohorts to determine its value as a diagnostic and prognostic 
marker in human CRC. Additionally, our data indicated that DATE mutation is the result of 
underlying MMR defects and DATE status was a highly sensitive indicator of genomic instability, 
as it was capable of detecting MSI with more precision than the current gold-standard markers of 
instability. These discoveries suggested that DATE mutagenesis is likely an early event in the 
process of CRC tumorigenesis. To determine the point at which DATE truncation occurs during 
the tumorigenic process, early and late stage colorectal adenomas could be assessed for DATE 
status. If DATE mutagenesis and autocrine HGF production are found to be early events during 
the tumorigenic process, additional clinical studies could be performed to determine whether 
using HGF-Met inhibition as front-line therapy for early stage CRC is advantageous in improving 
overall patient prognosis. Conclusively, our findings invite further exploration of the role of 
aberrant HGF-Met signaling in CRC, and encourage the development of DATE as a novel 
biomarker to guide the personalized treatment of human CRC. 
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